The journey of SARS-CoV-2 in human hosts: a review of immune responses, immunosuppression, and their consequences

Amal F. Alshammary and Abdulrahman M. Al-Sulaiman

ABSTRACT
Coronavirus disease 2019 (COVID-19) is a highly infectious viral disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Laboratory findings from a significant number of patients with COVID-19 indicate the occurrence of leukocytopenia, specifically lymphocytopenia. Moreover, infected patients can experience contrasting outcomes depending on lymphocytopenia status. Patients with resolved lymphocytopenia are more likely to recover, whereas critically ill patients with signs of unresolved lymphocytopenia develop severe complications, sometimes culminating in death. Why immunodepression manifests in patients with COVID-19 remains unclear. Therefore, the evaluation of clinical symptoms and laboratory findings from infected patients is critical for understanding the disease course and its consequences. In this review, we take a logical approach to unravel the reasons for immunodepression in patients with COVID-19. Following the footprints of the virus within host tissues, from entry to exit, we extrapolate the mechanisms underlying the phenomenon of immunodepression.

Introduction
Coronavirus disease 2019 (COVID-19) is a highly infectious viral disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1]. COVID-19 was first identified in late December 2019, when a cluster of patients were diagnosed with pneumonia of unknown cause. These patients were linked epidemiologically to the seafood and wet animal wholesale market in Wuhan, Hubei Province, China [2]. Soon after, the disease spread globally, leading to declaration of the COVID-19 pandemic by the World Health Organization [3]. As of April 2021, the disease has spread to 192 countries, with more than 136 million confirmed cases and over two million deaths [4], thus becoming the first pandemic of this century and a critical concern worldwide.

Laboratory findings from a significant number of patients with COVID-19 indicate the presence of leukocytopenia, specifically lymphocytopenia [5,6]. Leukocytopenia is a marked decrease in all white blood cells (WBCs), including myeloid and lymphoid-derived WBCs (i.e., dendritic cells (DCs), macrophages, neutrophils, eosinophils, basophils, natural killer (NK) cells, B cells, and T cells). Lymphocytopenia is defined as a significant decrease of only lymphoid-derived WBCs (i.e., NK, T, and B cells). Both leukocytopenia and lymphocytopenia result in the clinical state of immunodepression/immunosuppression. Moreover, infected patients have been shown to experience contrasting outcomes depending on lymphocytopenia status. Patients with resolved lymphocytopenia are more likely to recover, whereas critically ill patients with signs of unresolved lymphocytopenia develop severe complications, sometimes culminating in death [5–7].

Lymphocytopenia is clearly not an ideal setting in which to fight a viral infection; however, the occurrence of this clinical picture in patients with COVID-19 is unsurprising, as it has been observed in other severe viral infections, including Avian-flu, Swine-flu, SARS, and MERS [8–13]. Nevertheless, lymphocytopenia in the face of viral infection contradicts the physiological function of immune cells, whose sole purpose is to rid the body of foreign entities. Thus, either the invading microbe (in this case, SARS-CoV-2) induces this depression to favor its own survival inside host cells, or there is a failure of the host immune system to fight the disease. Based on this assumption, it is critically important to investigate the underlying pathophysiological mechanisms in patients with COVID-19. The lymphocytopenia observed in these patients is a critical sign of a disrupted immune response, which is alarming, as immune irregularities render patients prone to disease. Moreover, it is not clear why...
lymphocytopenia manifests in COVID-19 patients. Therefore, the evaluation of clinical symptoms and laboratory findings from infected patients is critical for understanding the disease course and its consequences.

This review takes a logical approach to unravel the causes of immunodepression, specifically lymphocytopenia, in COVID-19 patients by following the footprints of the virus within host tissues from entry to exit and collating information about the mechanisms underlying this phenomenon. Given the relatively short period of time since the emergence of SARS-CoV-2, conclusive data on SARS-CoV-2 pathophysiology inside host tissues are scarce. Therefore, where relevant, host immunological events common in response to coronavirus family members are summarized and related to SARS-CoV-2 or coronavirus family members more generally.

**Clinical manifestations and transmission in COVID-19**

Infection with SARS-CoV-2 does not automatically result in disease, and infected subjects can be classified into four main groups according to clinical presentation. The first group are asymptomatic, with no signs or symptoms observed clinically; however, anosmia (loss of smell) and dysgeusia (loss of taste) are common among patients positive for the virus even in the absence of other symptoms [14–16]. The second group present with flu-like symptoms, including fever, fatigue, sputum production, sore throat, and cough [5,6]. The third group present with further symptoms, ranging from mild to severe, including headache, unproductive cough, persistent chest tightness, and difficulty breathing [2,5]. Additionally, a few cases have reported nausea, vomiting, and diarrhea, although this is uncommon [7,17]. Finally, as the disease progresses, the fourth group present with severe life-threatening complications, including pneumonia, acute lung injury (ALI), acute respiratory distress syndrome (ARDS), multiple organ failure, septic shock, and sometimes, death [18,19]. Asymptomatic subjects are considered possible carriers and may or may not spread the infection, whereas symptomatic patients are highly contagious [20–22]. Reports vary greatly with regard to the incubation period from infection to disease onset, and have included ranges as restricted as 5–6 days and as extended as 2–14 days [23,24]. Moreover, preliminary reports estimate the basic reproduction number ($R_0$) of the virus is between 1.4 and 3.8, indicating pandemic potential and the possibility of sustained infections within communities [25–28].

Although it is early to calculate infection and fatality frequencies among infected populations, preliminary reports from several affected countries demonstrate that the majority of severe cases and fatalities are among older adults and patients with underlying illnesses [29,30]. Moreover, although it has been reported that fatalities occur among young adults and not in children, reports of children dying from the disease have begun to emerge [31–33]. Furthermore, infected male patients are more vulnerable to the disease than female patients, as the majority of patients who develop severe complications or death are male [34]. In addition, earlier reports showed that pregnant women with confirmed COVID-19 developed symptoms similar to non-pregnant COVID-19 patients [35–38]. However, recent studies reported that COVID-19 pregnant women are at high risk of developing severe complications compared to non-pregnant COVID-19 patients [39,40]. Further, pregnant women with confirmed COVID-19 in their third trimester did not show signs of intrauterine vertical transmission to their fetus, thus reported to be at high risk of preterm delivery due to fetal distress [35,36,41].

**SARS-CoV-2 genome organization and expression**

SARS-CoV-2 belongs to the β-coronaviruses, which are known to infect mammals [1]. They contain a non-segmented positive sense single-stranded RNA (+ssRNA) genome of about 30 kb, organized in a typical coronavirus genome pattern as follows: 5’-untranslated region (UTR), replicase open reading frame 1ab (ORF1a/ORF1b), spike glycoprotein (S), envelope protein (E), membrane protein (M), nucleocapsid protein (N), non-structural open reading frames (NS-ORFs), 3’-UTR [1,42,43] (Figure 1A). Two-thirds of the viral RNA (around 20 kb) is occupied by replicase genes and encodes non-structural proteins (NSPs), while the remainder (approximately 10 kb) encodes structural and accessory proteins [44,45].

Coronaviruses have a unique genome configuration as their +ssRNA can act as a messenger RNA (mRNA) from which coding sequences are directly translated into proteins upon reaching the cell translation machinery, namely ribosomes [43,46]. This is possible because the viral genomes contain sequences similar to those of cellular mRNAs with a 5’-cap (leader) and 3’-poly adenylated (A) tail (body) which creates a mature RNA template that can undergo translation. This process usually initiates at the 5’ end, which restricts translation to the first ORF; however, coronaviruses have a polycistronic genome.
Overall, translation of replicase ORFs, including ORF1a and ORF1b, results in the synthesis of two large replicase polypeptides, pp1a and pp1b, that undergo proteolytic cleavage. This is mediated by internal proteases encoded by ORF-1a NSPs, which process the two replicase polypeptides to yield 15 or 16 active proteases [50]. Consequently, replicase polypeptides initiate the generation of nested RNAs encoding the structural-ORFs, which give rise to the four main structural proteins: S, E, M, and N [51,52]. The S glycoprotein mediates attachment and virus entry into host cells, and is comprised of two subunits: S1, which determines virus-to-host cellular tropism, and S2, which mediates virus-to-cell membrane fusion.
Both subunits are expressed on the surface of the virion as a club-like shaped trimer, giving the virus the appearance of a solar crown, hence the name, crown-like or corona [53]. The M protein is expressed as a transmembrane dimer and is thought to give the virion its spherical shape [43]. Moreover, M protein is the most abundant envelope protein and may serve as a connector, binding the virion envelope to the helical nucleocapsid [56]. Similarly, E protein is thought to be a transmembrane protein, and although present in small quantities, appears to play a key role in promoting viral pathogenesis [57–59]. In contrast, the N protein is the sole protein constituent of the nucleocapsid and is capable of binding to the viral genome in vitro [60–62] (Figure 1B). Finally, the translation of accessory protein ORFs generates proteins considered non-essential, which nevertheless promote virus pathogenicity and modulate host innate immunity [63,64].

The SARS-CoV-2 life cycle

Specific details regarding the SARS-CoV-2 life cycle inside host cells have yet to be determined; however, knowledge of other coronavirus family members, including severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory-related coronavirus (MERS-CoV), may provide clues as to the life cycle of SARS-CoV-2 [66]. For these viruses, the life cycle begins upon host entry via respiratory droplets, where they target respiratory epithelial cells, especially alveolar epithelial cells of the lung. These cells express high levels of the receptor needed for entry of SARS-CoV-2, angiotensin-converting enzyme 2 (ACE2), which is the same receptor used by SARS-CoV to infect humans [67–69]. This receptor was quickly identified based on the fact that SARS-CoV and SARS-CoV-2 share 79% similarity [70–72]. ACE2 is found mostly in the lower respiratory tract, where SARS-CoV-2 causes the most damage [73]. Further, SARS-CoV-2 has been detected in bronchoalveolar lavage fluid (BALF) isolated from a patient with COVID-19 [70].

SARS-CoV and MERS-CoV follow similar entry routes after cellular attachment; however, MERS-CoV binds to the dipeptidyl peptidase 4 (DPP4) receptor on host cells. Regardless of the entry receptor, these viruses target respiratory epithelial cells [74–77]. Entry into host epithelial cells is initiated once the virus particle is engulfed with its envelope intact. Once inside the endosomal vesicle, induced lysosomal proteases cleave the viral S glycoprotein, mediating fusion of the viral envelope with the host endosomal membrane [78,79]. Subsequently, the naked virion is released into the cytoplasm where nucleocapsid proteins disassociate, liberating the viral +ssRNA [80,81]. Once the +ssRNA is released into the cytoplasm, it moves to host ribosomes where the genome is decoded, proteins are synthesized, and infectious progeny are produced [82].

Coronavirus replication and assembly is associated with both the rough endoplasmic reticulum (ER) and Golgi complex, as several studies have revealed that virion particle formation occurs in the intermediate compartment of smooth-walled tubulovesicular membranes between the ER and Golgi complex (ERGIC) [83–89]. Following translation, the viral structural proteins, S, E and M, are inserted into the ER and eventually transported into the secretory pathway of the ERGIC, forming empty, assembled virus-like particles (VLPs) [90–92]. Subsequently, the translated N protein polymerizes around the newly synthesized viral genome to form the nucleocapsid [93]. Finally, the N-protein-encapsidated full-length viral genome buds into the ERGIC complex, which contains associated envelope and structural proteins, to form a mature virion [94,95].

Assembled virions exit the cell in the same way they enter, within an endosomal vesicle, and thus their outbound route is via exocytosis [96] (Figure 2). However, mature virus particles do not exit separately, as multiple virions are engulfed inside a giant endosomal vesicle from which they exit together as a group [43]. This deceptive egress allows the virus to spread quickly before being detected by resident and circulating immune cells near the infected cells. Electron microscopy (EM) visualization of SARS-CoV-2-infected epithelial cells isolated from a patient with COVID-19 showed giant vesicles containing multiple virions present in the cytoplasm, whereas single virions were observed extracellularly. Thus, this confirms this method of egress, or budding, following infection [2].

Cell injury following SARS-CoV-2 infection

SARS-CoV-2 infection causes severe damage to epithelial cells, triggering cell death. As the virus continues its invasion into neighboring cells, the epithelial lining becomes excessively inflamed and damaged, eventually leading to the development of ARDS [7,97]. It is not yet clear how cell death occurs following SARS-CoV-2 infection; however, lung autopsy reports from patients with SARS-CoV and MERS-CoV revealed epithelial cell necrosis, alveolar fibrosis, and diffuse alveolar damage [98–100]. These histological features suggest that necrotic death, rather than autophagy or apoptosis, occur following infection. This may be partly due to the fact that the virus is shed through transport within a large vesicle that eventually merges with the plasma.
membrane thus destabilizing its surface. Following infection with coronaviruses, epithelial cells lose their ciliated surfaces. This damage may be associated with the newly formed endosome-plasma membrane structure \[100–102\]. Indeed, the dry cough associated with severe pneumonia supports this hypothesis, as it is a clinical symptom that results from reduction of or damage to the ciliated surface responsible for the movement of mucous. It should be noted, however, that several studies have demonstrated the induction of apoptosis in tissues from multiple organs following infection with SARS-CoV-2 \[103,104\]. Thus, we speculate that induced apoptosis is a consequence of a dysregulated immune response, while necrotic cell death is the result of viral replication inside permissive cells. Thus, non-permissive cells may undergo induced apoptosis following intracellular immune recognition of viral components. Moreover, it is also possible that necrotic cell death predominates during the early stages of infection. As the disease progresses and immune dysregulation becomes prominent, apoptosis or autophagy may become the main cause of cellular death. Indeed, it has been previously proposed that cell death can be induced via different mechanisms during
infection, although more studies are needed to prove or disprove these hypotheses [105].

While autophagy or apoptosis of permissive epithelial cells are possible during the early stages of viral infections, they are unlikely for two reasons [1]: the extensive damage observed in the lung, including fibrosis, do not usually occur following autophagy or apoptosis [2]; the exaggerated immune reaction and cytokine production at the site of infection indicate necrotic cell death, rather than autophagy or apoptosis, which are considered clean types of cell death not requiring a heightened immune response. This is important, as both the virus replicative cycle and resultant cellular injury define the nature of the activated immune responses. As the virus sheds, host immune cells should recognize either the virus, the injured cell, or both. Consequently, it is critical to understand the nature of the immune reactions exerted in this scenario, as both can result in inflammation that translates to excessive cytokine production, known as a cytokine storm. Understanding this concept leads to the logical conclusion that treatment targets must be based on the underlying cause. Thus, whether a cytokine storm arises due to virus recognition or cell death must be determined to identify the cause of immunodepression observed in patients with COVID-19 and to find an effective treatment solution.

**Immune recognition**

The human immune system has a dual nature, with innate and adaptive arms. Innate immunity is nonspecific, and recognizes antigens without the need for previous encounters with invading microbes. Innate immune cells include: DCs, macrophages, neutrophils, eosinophils, basophils, and NK cells. In contrast, adaptive immunity is specific and requires antigen presentation through antigen presenting cells (APCs) (primarily DCs), which activate adaptive immune cells (B and T cells) to produce effector progeny that can combat disease in a directed manner. Because SARS-CoV-2 has not previously encountered by humans, the innate immune response to this pathogen is likely of central importance.

Innate immune cells recognize structurally conserved molecules through pattern recognition receptors (PRRs), which can be membrane bound, such as Toll-like receptors and C-type lectin receptors, or cytoplasmic, such as nucleotide oligomerisation domain-like receptors and RIG-I-like receptors [106–108]. Moreover, depending on the nature of the target antigens, innate PRRs recognize and bind two types of structures. If foreign (non-self) antigens are present, PRRs bind to common pathogen structures, known as pathogen-associated molecular patterns (PAMPs) [109,110], whereas PRRs bind to damage or danger associated molecular patterns (DAMPs), also known as alarmins, on non-self (self) antigens [111–113]. PAMPs include signature microbial structures, such as surface glycoproteins, cellular and non-cellular structures, and microbial nucleic acid [114]. In contrast, DAMPs include a varying repertoire of host biomolecules that are usually intact or confined within the cell, but are released as a result of cell injury or necrotic cell death. These include degraded extracellular matrix proteins or intracellular molecules (cytosolic and nuclear proteins) [115].

In COVID-19, the virus can be detected in patient samples, leading to the assumption that PPRs must be binding to PAMPs (viral components). Moreover, patient radiographs, CT scans, and laboratory profiles confirm that active cellular damage occurs and thus, PPRs must also be binding to DAMPs (cellular components). Surprisingly, whether binding PAMPs or DAMPs, PRRs activate similar pathways, regardless of the nature of the stimulating antigen [116–119]. This phenomenon is beneficial, as it reflects immune system recognition of the cellular damage mediated by microbial infection. Further, this strategy highlights the sophistication of the human immune system, which helps to restrict both microbial replication and cellular damage from reaching other organs and causing additional complications. Thus, the magnitude of the immune response corresponds to the number of inducing antigens (self and non-self) present at the site of infection [117,120]. Understanding the consequences of PRRs binding to PAMPs and DAMPs will enable further understanding of the clinical picture presented in COVID-19.

**Innate immune responses**

PAMP/DAMP-associated molecules at the site of infection trigger a potent innate immune response that corresponds to the extent of tissue damage [121–123]. More virus components and increased cell damaged result in augmented recruitment of innate immune cells to the site of injury, leading in turn to greater cytokine production. This phenomenon can result in a systemic hyper-inflammatory response, known clinically as systemic inflammatory response syndrome (SIRS) [120,123,124]. Several lines of evidence indicate that, following SIRS, a secondary immune response, known as the SIRS-like immune response, is initiated to boost antimicrobial defense mechanisms [125,126]. This strategy is remarkable, given that extensive
damage and immune recruitment to the site of injury can leave the body defenseless against resident microbial flora, which will inevitably cause added insult to tissues and organs. Both, SIRS and SIRS-like immune responses result in the clinical phenomenon described as a cytokine storm [126–128]. The immune system senses the level of damage caused by this exaggerated cytokine release, which can overwhelm the physiological system, leading to unintended damage. Consequently, a third immune response is induced to reduce the collateral damage generated by the cytokine storm. This third response manifests as an anti-inflammatory response, known as counterbalancing compensatory anti-inflammatory response syndrome (CARS) [129–131]. Initiation of CARS induces down-regulation of immune cells, reflected in the numbers of lymphocytes observed following injury and resulting in a condition referred to as post-traumatic immunosuppression [132,133]. SIRS/SIRS-like responses and CARS are contrasting phenomena, the first results in hyper-inflammatory cytokine production, whereas the latter produces a reduction in inflammatory cytokines. Both syndromes occur simultaneously and correlate with patient status and the extent of injury [132,134]. SIRS is mediated by macrophages, while SIRS-like secondary immune responses are predominantly mediated by both macrophages and neutrophils, and CARS is mediated by T cells [135–139]. Patients can present with any of the following: SIRS, with a pro-inflammatory response; mixed SIRS and CARS with both pro- and anti-inflammatory responses; and finally CARS with an anti-inflammatory response [125,132,135].

This dual immune response is observed in patients with severe COVID-19, as laboratory findings support the co-occurrence of a cytokine storm and immunosuppression. Surprisingly, this clinical/laboratory picture is a mirror image of what happens during severe trauma, as microbial and non-microbial injuries result in sepsis, septic-shock, and multiple organ failure [140,141]. Thus, a rapid review reveals that COVID-19 mimics the pathophysiology observed in response to severe injuries. This observation indicates that what is known about the nature of immune responses and cytokine production in trauma can be applied to COVID-19, which could aid in the pursuit of better solutions to combat this disease.

**Ground-zero cytokines**

Upon identification of a cytokine storm following injury, the type of cytokines present and cells responsible for their secretion must be identified. Both immune and nonimmune cells are known to secrete specific sets of cytokines with overlapping functions. Therefore, it is difficult to determine the nature of cytokines produced and which cells are responsible, since many cells are involved in this scenario. However, a logical approach is to follow the causative agent and identify the first cellular responder. This presumed first contact will lead to secretion of cytokines responsible for the recruitment and activation of corresponding cells, which in turn secrete their own cytokines generating a cytokine network. The causative agent and first cellular responder produce what are known as ground-zero cytokines, from which all following reactions stem.

The underlying mechanisms occurring within the respiratory system in response to inhaled particles enable reconstruction of the pathway from which the causative agent, in this case SARS-CoV-2, emerges from respiratory droplets reaching the lung. Normally, inhaled particles larger than 10 μm are deposited onto the mucous-coated ciliated-epithelium surface lining the nose, pharynx, trachea, and conducting airways [142]. Such mucous-trapped particles in the lower conducting airways are then expelled through a process known as the mucociliary escalator, whereby the beating movement of ciliated-epithelia transports mucous-trapped particles in an upward motion toward the mouth [142–144]. This process is facilitated by the functions of sneezing, coughing, and swallowing mucous-trapped particles. In contrast, inhaled particles smaller than 5 μm pass through the conducting airways and land on the surface of bronchiolar–respiratory duct junctions or, alternatively, are deposited onto the surface of alveoli [142]. At this site both resident alveolar macrophages, located adjacent to lung alveoli, and pulmonary DCs, located beneath the alveolar basement membrane, provide protection from incoming inhaled particles [145].

Due to their size, SARS-CoV-2 particles most likely enter in respiratory droplets and land on the surface of lung alveoli. ACE2 receptor expression and alveoli damage following infection support this theory [2,72]. From there, some virus particles will come in contact with resident alveolar macrophages, some will be sampled by lung-resident DCs, and others will escape and go on to infect alveolar epithelial cells, which may recognize the virus after it begins its replicative cycle in the cytoplasm [146–148]. In contrast, alveolar macrophages, given their location adjacent to the alveolar epithelium and the fact that their numbers exceed those of lung-resident DCs, recognize virus particles on contact. This reconstructed pathway suggests that resident alveolar macrophages are likely the
first responders, followed by alveolar epithelial cells and lung-resident DCs. Based on this assumption, alveolar macrophages would be responsible for production of the ground-zero cytokines referred to above. The next question to explore is the nature of these cells and the mechanisms underlying their cytokine secretion, as well as the cells they communicate with and their corresponding cytokine responses. Decoding cellular communications in this setting will aid efforts to reveal the nature of the cytokine storm produced following SARS-CoV-2 infection.

**Cellular recruitment and cytokine production**

Resident alveolar macrophages are professional phagocytes, constituting more than 90% of total hematopoietic cells present in bronchoalveolar lavage fluid [149–152]. Their main function is to protect the airway from foreign microbial and non-microbial antigens, as well as to clear cellular debris; however, they are also responsible for post-infection remodeling of the lung parenchyma [153–159]. These macrophages maintain lung homeostasis by preventing unnecessary immune responses against harmless inhaled particles, which could cause unnecessary lung injury and interfere with alveolar-gas exchange [160–162]. Resident alveolar macrophages maintain this dampened immune characteristic of the lung by producing anti-inflammatory cytokines necessary to block unwanted alveolar inflammation [163–165]. Several cytokines produced by resident alveolar macrophages can suppress alveolar inflammation, including transforming growth factor β (TGFβ) [166,167]. Additionally, secretion of interleukin 10 (IL-10) and prostaglandin E$_2$ supresses adaptive immunity through blocking the activation of both DCs (communicators with adaptive cells) and T cells [160,162]. Similarly, alveolar epithelial cells produce IL-10 and suppress the activation of alveolar macrophages [168]. Moreover, lung-specific surfactant proteins A and D (SP-A/SP-D) have key roles in maintaining the suppressive phenotype of resident alveolar macrophages through binding to calreticulin and CD91 receptors on the surface of resident alveolar macrophages [169,170]. It should be noted that during infections SP-A and SP-D bind to PAMPs removing their suppressive function on resident alveolar macrophages. As a consequence, CD91 on the surface of these macrophages is free and instead bind to PAMPs [169]. CD91/PAMP signaling alters the phenotype of resident alveolar macrophages, which begin to secrete pro-inflammatory cytokines with direct effects on the alveolar epithelium and serve as inflammatory signals for the recruitment of circulating monocytes and polymorphonuclear cells.

IL-1β and tumor necrosis factor α (TNFα) are the first cytokines produced by resident alveolar macrophages in response to microbial stimulants [142]. Due to their location, the first responders to these cytokines are alveolar epithelial cells, which upregulate the expression of chemokine ligand 2 (CCL2), thereby attracting circulating monocytes and neutrophils expressing chemokine receptor 2 (CCR2) to the site of infection [171–174]. Additionally, several chemokines are upregulated in alveolar epithelial cells following lung infections, including CCL3, RANTES (CCL5), IL-8/CXCL8, and interferon-γ-inducible protein (IP10/CXCL10) [174]. Moreover, studies on animal models susceptible to SARS-CoV infection revealed that alveolar epithelial cells upregulate the expression of potent monocyte and neutrophil recruitment molecules, such as the adhesion molecules P-selectin, vascular cell adhesion protein 1 (VCAM-1), and DC-specific intracellular adhesion molecule-3-grabbing non-integrin (DC-SIGN) [174,175]. During viral infections (other than coronaviruses), virus-infected epithelial cells secrete interferon β (IFNβ) causing neighboring cells to produce anti-viral proteins that inhibit viral replication in non-infected cells. Of note, SARS-CoV induces a dysregulated immune response by blocking the production of several pro-inflammatory cytokines and chemokines including, IFNα, IFNβ, IFNγ, TNF, CCL5 and CXCL10 [174–178].

The next immune responders are lung-resident DCs, which are situated at the basolateral side of the epithelium and extend their projections (dendrites) into the lumen of alveoli and conducting airways to sample antigens without disrupting the intact epithelial barrier layer [179–182]. Once antigens are captured, lung-resident DCs migrate to local draining lymph nodes to present processed antigens to T cells [183,184]. Normally, lung-resident DCs express E-cadherin-binding integrin (αEβ7), and CCR6 [185–187]. Following viral infection, these DCs immediately respond to TNFα and CCL20, inducing their dispatch to local lymph nodes for antigen presentation [188,189]. However, DC activation does not trigger local inflammation, as T cell activation following bacterial challenge is minimal [162,179,190]. Moreover, several studies have shown that T cells extracted from mucosal lymph nodes exhibit Th2 polarity upon activation [191,192]. Studies on animal models indicate that the DC population is heterogenous. However, two classical subtypes can be identified by their cytokine production and ability to stimulate specific T cell subsets, IL-12 DCs, which stimulate proliferation of Th1 cells,
and IL-10 DCs, which stimulate Th2 cell proliferation [193]. Collectively, these findings confirm the regulatory role of lung-resident DCs in preventing local inflammation during lung infections.

Endothelial cells are another key local responder during lung infections. These cells line blood vessels beneath the basement membrane of lung alveoli providing the ideal interface for gas exchange. However, inflammatory mediators released by alveolar epithelial cells and alveolar macrophages promote vasodilation and increase permeability to permit leukocyte influx into infected areas. Moreover, released cytokines travel through blood vessels and subsequently stimulate the recruitment of circulating leukocytes. In addition, vasodilation causes fluid to escape into the interstitial space beneath lung alveoli resulting in edema and alveolar shrinkage, which can progress to development of pneumonia, ALI, and ARDS [194,195]. Studies on influenza viral infection of the lung revealed induction of pro-inflammatory cytokine expression by endothelial cells, including IL-6, IL-8, TNFα and TNFβ [196]. Collectively, endothelial cytokines may contribute to the cytokine storm observed following lung infection and consequent localized edema. This can result in systemic infiltration of fluids affecting multiple organs, and not just the lung.

Regarding cellular responders from outside the lung, neutrophils arrive to the injury site within minutes and, under normal circumstances, are the first to die, within 24 hours of their dispatch from the bone marrow [197–199]. Neutrophils participate in microbial clearance through their production of hydrogen peroxide (H₂O₂), superoxide anion, microbiocidal proteins, and extracellular traps (NETs). However, following severe trauma or viral infection, neutrophils can exhibit a prolonged lifespan through their ability to resist intracellular or extracellular apoptotic signals under such circumstances [199–203]. Consequently, an increase in circulating neutrophils, referred to as neutrophilia, is a common outcome in many viral infections [204]. Further, neutrophils with prolonged lifespans exhibit heightened aggression, causing indirect damage within injured tissues [205–210].

The next cells to contribute are circulating monocytes, which differentiate into macrophages upon reaching tissues. The demands encountered by monocytes at target locations dictate their differentiation into specific macrophage subtypes, each with unique characteristics and cytokine profiles [211]. Subtype I macrophages are responsible for clearing cellular debris and dead neutrophils, and secrete anti-inflammatory cytokines, such as tumor growth factor β (TGFβ) and IL-10 [212–214]. In contrast, subtype II macrophages recognize DAMPs and secrete pro-inflammatory cytokines, such as IL-1β, IL-6, IL-8/CXCL8 and TNFα, in addition to inducible nitric oxide synthases [215–221]. Moreover, subtype II macrophages produce several chemokines, including CCL2, CCL7 and CCL12, resulting in further accumulation of recruited inflammatory cells [222,223]. Based on their cytokine production, subtype I macrophages are mainly responsible for the repression of adaptive immune cells, whereas subtype II macrophages are responsible for the cytokine storm observed following lung infections [224,225].

 Mast cells are another key player in this cellular constellation. Further, the role of mast cells in lung immunopathology following viral infections is often underestimated. Readily available to respond to invading microbes, mast cells are strategically located near blood vessels, regional lymph nodes, and nerve endings, allowing them to modulate host responses to invading pathogens [226,227]. Mast cells contain powerful granular mediators that are immediately released upon activation, including TNFα, β-hexosaminidase, amines, histamine, serotonin, antimicrobial peptides and proteases (tryptases and chymases) [228–231]. In addition, mast cells release preformed granules within a few minutes of an injury containing factors such as prostaglandins and leukotrienes. Preformed cytokines and growth factors, including IL-4, IL-5, IL-6, IL-13, IL-17, TNFα and vascular endothelial growth factor (VEGF), are released by mast cells a few hours later [231–233]. Cytokines, chemokines, and chemical mediators released by mast cells following infection lead to increased epithelial and endothelial cell permeability, which in turn results in increased cellular recruitment and infiltration (Figure 3).

Although the cytokine storm produced following lung injury or infection is responsible for the immunopathology observed in patients with COVID-19, immune cell recruitment to injured tissues mainly involves innate cells, such as neutrophils, monocytes and mast cells, rather than adaptive immune cells. Thus, the purpose of the cytokine storm is thought to be the recruitment of myeloid, rather than lymphoid, cells. Nevertheless, lymphoid cell fate during viral lung infection is crucial, since the presence of certain lymphocyte populations can predict the severity and outcome of COVID-19.

**Lymphocyte subsets**

A reduction in lymphocytes is associated with severe injuries and unresolved infections [234–243]. The initiation of a cytokine storm following infection clearly contributes to this reduction, as the storm serves to
Innate immune responses in lung infections. Coronavirus particles causing COVID-19 most likely enter the body via respiratory droplets and land on the surface of lung alveoli. From there, some virus particles will come in contact with [1] resident alveolar macrophages followed by [2] alveolar epithelial cells. The next immune responders are [3] lung-resident dendritic cells situated at the basolateral side of the epithelium with projections (dendrites) extended into the lumen of alveoli and conducting airways to sample antigens without disrupting the intact epithelial barrier layer. Another key local responder during lung infection is [4] endothelial cells. These cells line blood vessels beneath the basement membrane of lung alveoli. However, inflammatory mediators released by alveolar epithelial cells and alveolar macrophages promote vasodilation and increase permeability to permit leukocyte influx into infected areas. Moreover, released cytokines travel through blood vessels and subsequently stimulate the recruitment of circulating leukocytes. In addition, vasodilation causes fluid to escape into the interstitial space beneath lung alveoli, resulting in edema and alveolar shrinkage. Regarding cellular responders from outside the lung [5], neutrophils arrive to the injury site within minutes. The next cells to contribute are [6] circulating monocytes, which can differentiate into macrophages on reaching tissues. Another key player in this cellular constellation is [7] basophils (mast cells within tissues), readily available to respond to invading microbes, as they are strategically located near blood vessels, regional lymph nodes and nerve endings, allowing them to modulate host responses to invading pathogens. Made with BioRender [65].

Recruit myeloid, rather than lymphoid, cells [244,245]. However, it should be noted that DCs, which are of myeloid origin, are also reduced [246,247]. This phenomenon can be explained through understanding of the basic physiological function of these cells. DCs are professional phagocytic cells, which primarily ingest foreign particles and later present them to T helper (Th) cells, thereby serving as the main initiators of adaptive immune responses. *In vitro* studies have shown that naïve T cells are only stimulated by DCs, which may explain why a reduction in DC counts prevents activation of adaptive immune responses [248]. Moreover, several studies have demonstrated that apoptosis is induced following viral infection resulting in a massive depletion of follicular DCs in addition to T cells (CD4 and CD8), B cells, and NK cells [246,249,250]. In addition, circulating CD4 and CD8 T cells exhibit increased expression of programmed cell death protein 1 (PD-1), which inhibits their activation and cytotoxic functions [251–254].

Although T cell subsets are reduced following a cytokine storm, this reduction is selective and depends on the T cell subset. Several studies indicate that CD4⁺CD25⁺Foxp3⁺ T regulatory (Treg) cells are increased following viral sepsis and contribute to the depressed immune environment through their
increased production of IL-10 [242,255–257]. Unlike CD4 and CD8 T cell subsets, Tregs are resistant to sepsis-induced apoptosis and cause further insult to CD4 T cells, inducing their elimination or apoptosis through activation of the transforming growth factor β1 (TGFβ1) signaling pathway [237,258–260]. Moreover, increased Treg numbers indicate an inferior condition in septic shock patients and are associated with poor outcomes [256,257]. Similarly, CD4 T cells biased toward Th2 have been linked to a fatal outcome following viral sepsis [261–263]. This was linked to Treg secretion of IL-10, which promotes Th2 polarization of immune cells [262,264]. In vitro studies revealed that the major source of IL-10 secretion is Th1/2 and Th17 cells [265,266], which blocks CD4 T cell activation by inhibiting their production of pro-inflammatory cytokines, including IL-2, IL-5, TNFα, IFNγ and GM-CSF [267]. Indeed, IL-10 production by Th cell subsets is thought to regulate immune responses and provide protection from immunopathology during infection, while simultaneously suppressing activation of adaptive immune responses, manifesting clinically as the immunosuppression observed in unresolved infections.

**Lymphocytopenia in COVID-19**

A reduction of peripheral lymphocyte counts, including CD4+ and CD8 + T cells, B cells and NK cells, has been observed in COVID-19 patients [268–272]. Further, SARS-CoV-2 has been shown to induce a relative loss of lymphoid cells coupled with myeloid cell expansion in COVID-19 patients [273]. This reduction has been linked to disease severity and survival, as severe and fatal cases show a significant reduction compared to mild or recovered COVID-19 cases [274,275]. Thus, lymphocytopenia is more evident in the elderly and patients with underlying conditions such as hypertension, heart disease, diabetes, chronic obstructive pulmonary disease (COPD) and cancer [29,276,277]. Interestingly, lymphocytopenia is rarely detected in children, with less than 10% of SARS-CoV-2 infected children presenting with lymphocytopenia; however, when lymphocytopenia is detected in children it is usually found to be associated with complicated or severe cases [278–282].

The phenotypic and functional characterization of T cell subsets clearly indicates a defective cellular response in COVID-19 patients. T cells play an essential role in cellular immune regulation and viral clearance. A retrospective study conducted by Diao et al. indicated a 70% decrease in the levels of CD4+ and CD8 + T cells within non-ICU COVID-19 patients, and this reduction was more evident in ICU patients (reaching up to 95%) [283]. The fact that T cell populations, including CD4+ and CD8 + T cells, are reduced in COVID-19 patients suggests impaired or dysregulated cellular immunity in these patients and may be explained by several mechanisms. A study by Notz et al. reported a decrease in naïve Th cells in severe COVID-19 cases [284], which may indicate an impairment of T cell proliferation, maturation, and activation [285]. Another study performed by Rendeiro et al. showed that in COVID-19 patients T cells display overexpression of exhaustion and dysfunction markers such as the v-domain Ig suppressor of T cell activation (VISTA), T cell immunoglobulin and mucin-domain containing-3 (TIM-3), lymphocyte activation gene 3 (LAG-3), T cell immunosuppressor with Ig and ITIM domains (TIGIT), and PD-1 [273,286]. In line with this finding, Chen et al. and Sadeghi et al. reported increased levels of the pro-inflammatory Th17 cells, a major source of IL-10 production [272,287]. Thus, IL-10 secretion may induce T cell exhaustion as animal models of chronic infection have been shown to reverse T cell exhaustion following IL-10 blockade [288,289]. Furthermore, the accumulation of overactivated T cells in the lung during disease may cause reduced T cell counts in the peripheral blood. Wang et al. reported increased expression of the activation marker HLA-DR and the co-stimulatory molecule CD28 in severe COVID-19 patients [290,291]. Consistent with this finding, overactivated T cells have been found to predominate leukocyte infiltration in the lung following SARS-CoV-2 infection, which may reduce circulatory T cells in the periphery. At the same time this would promote T cell exhaustion, as it has been documented during chronic inflammation that continuous recruitment and stimulation of T cells can result in T cell exhaustion [292,293].

However, conflicting findings have been reported regarding Treg counts in COVID-19 patients. Chen et al. reported increased levels of Treg-enriched cells in COVID-19 patients [272]. The same study reported higher CD25 and lower CD127 expression in the Treg population, indicating enhanced functions of Tregs in suppressing the systemic inflammation observed in these patients. On the other hand, Flament et al. found a significant reduction in Tregs among SARS-CoV-2 infected patients compared to uninfected controls [294]. Similarly, Sadeghi et al. reported reduced levels of Tregs as well as the transcription factors retinoic-acid-receptor-related orphan nuclear receptor γ (RORγt) and forkhead box P3 (FoxP3) in severe COVID-19 patients [287]. In contrast, a study conducted by Tan et al. found similar Treg counts between
control and severe COVID-19 patients, which were higher compared to mild patients. This might highlight the negative regulatory role of Tregs in infected patients as their reduction seems to promote viral clearance [295]. Thus, the role of Tregs in COVID-19 remains unclear, which could be due to the timing of sampling from COVID-19 patients or to differences in the classification of patients upon admission. Therefore, further exploration of the regulatory and suppressive functions of these cells following SARS-CoV-2 infection as well as their influence on disease severity and patient survival is critically needed.

Similar to T cells, a reduction in B cells have been reported in COVID-19 patients, thus it has been found to be less pronounced compared to T cells [284,296,297]. Further, recent studies have shown that COVID-19 patients display reduced counts of naive B cells and increased levels of the exhaustion phenotype, CD21<sub>low</sub> B cells, which may explain the reduced B cell counts found in COVID-19 patients [284]. Interestingly, SARS-CoV-2 specific antibodies are detectable in the serum of COVID-19 patients, including IgG, IgM, IgA, and IgE [275,284,298]. In line with this finding, Wen et al. reported elevated levels of plasma cells in COVID-19 patients [299]. However, higher antibody titers and early seroconversion were found to be associated with increased severity in COVID-19 [275,298,300–302]. It is not clear why SARS-CoV-2 infected patients develop severe complications and sometimes fail to produce protective immunity against a subsequent infection while their antibody response seems to be unaffected. Thus, further studies are needed to explain this phenomenon.

Further, NK cells are innate lymphoid cells which can directly kill virally-infected cells, have also been found to be reduced in COVID-19 patients [70,299,303,304]. A retrospective study conducted on COVID-19 patients revealed a significant decrease in NK cell counts in severe cases, especially of the cytotoxic NK subset characterized as CD3<sup>+</sup>CD56<sup>dim</sup>CD16<sup>+</sup> [268]. In addition, several studies have reported the negative influence of SARS-CoV-2 infection on NK cell functions. Serum levels of perforin and Granzyme A (GrA) are reportedly significantly reduced in severe cases of COVID-19 compared to mild cases [268,305]. Thus, this indicates a dysregulated cytotoxic response and impaired ability to inhibit viral replication in severe COVID-19 cases. Although NK cells were found to be significantly reduced in COVID-19 patients, a significant NK cell accumulation was noted in BALF samples taken from the lungs of SARS-CoV-2 infected patients [306]. This could also be the reason for NK presentation of the exhaustion phenotype, as overstimulation occurring during COVID-19 infection could hamper cytotoxic activities of NK cells and induce cellular exhaustion [70]. In addition, the increased secretion of IL-6 following SARS-CoV-2 infection could suppress Granzyme B (GrB) production and the expression of NKG2D necessary for eliminating infected cells and eventually hinder the ability of NK cells to clear infected cells [305].

It became apparent early in the pandemic that higher neutrophil to lymphocyte (NLRs) ratios are predictive of disease severity in COVID-19 patients. A higher NLR was also found to be associated with lymphocyte impairment [302,307–310]. Further, elevated levels of serum neutrophil extracellular traps (NETs) have also been detected in SARS-CoV-2 infected patients. Zou et al. reported increased serum levels of several markers commonly used to detect NET remnants in blood including cell-free DNA, myeloperoxidase-DNA (MPO-DNA), and citrullinated histone H3 (Cit-H3) [311]. The same study also reported that patient serum displayed evidence of NETosis when added to control neutrophils [311]. Taken together, these observations indicate the role of neutrophils and their relation to lymphocyte counts in the pathogenesis of COVID-19.

**Cytokine profile in COVID-19**

Analysis of plasma from patients with COVID-19 has revealed increases in cytokines, including IL-1β, IL-2, IL-6, IL-7, IL-10, TNFα, monocyte chemoattractant protein (MCP1/CCL2), granulocyte colony stimulating factor (G-CSF), and macrophage inflammatory protein 1α (MIP1α/CCL3). Of this extensive list, recently published studies have zeroed in on several cytokines thought to be key players during SARS-CoV-2 infection. A cohort study by Huang et al. included 41 patients with COVID-19 and revealed that those requiring ICU admission (32%) presented with higher levels of cytokines, including IL-2, IL-7, IL-10, TNFα, G-CSF, CCL2, CCL3, and CXCL10 [7]. Similarly, Zhou et al. examined samples from 191 patients with confirmed COVID-19, of which 54 died, and found that IL-6 levels were higher in non-survivors than survivors [300]. Additionally, a recent retrospective study collected data from 121 patients with COVID-19 and found increased levels of IL-6 (35.2%) and IL-10 (64.4%) on hospital admission [312]. These findings strongly support the involvement of IL-6 and IL-10 in disease prognosis and outcomes during the early stages of COVID-19.

IL-10 is a pleiotropic cytokine mainly produced by macrophages and T cell subsets (Th and Treg), in
addition to a wide variety of other immune cells, including DCs, NK and B cells [313]. In vivo and in vitro studies have shown that IL-10 suppresses the function of pro-inflammatory cytokines, including IL-1α, IL-1β, IL-6, IL-8, IL-12, IL-18, TNFα, G-CSF and M-CSF [313-315]. Moreover, studies on monocyte/macrophage activation found that IL-10 restricts inflammatory responses by inhibiting the expression of MHC II and the co-stimulatory molecules, CD80/CD86, on APCs [316,317]. This is crucial because antigen presentation in adaptive immunity, specifically in relation to Th subsets, is driven by the expression of MHC II molecules on DCs. This finding indicates that the immunosuppression observed in COVID-19 patients is mainly driven by IL-10, hence blocking this cytokine may lead to better outcomes following SARS-CoV-2 infection.

**Discussion**

Lymphocytopenia is a common laboratory finding among patients with COVID-19. This is troubling, as lymphocytes are crucial to the adaptive immune response needed to fight infection. Moreover, reported cases of COVID-19 indicate that recovered patients present with increased lymphocyte counts relative to non-recovered patients, who exhibit persistently depressed lymphocyte numbers. This difference clearly indicates that immunosuppression is a pathological phenomenon predictive of complicated patient outcomes. Overall, this review summarizes the major immunological events that occur following SARS-CoV-2 infection, providing an in-depth analysis of key cellular components and cytokines involved in the immunosuppression observed in COVID-19. Collective data indicate that anti-inflammatory cytokines, including IL-10, are likely produced to limit the cytokine storm observed following SARS-CoV-2 infection; however, IL-10 fails to achieve this, as high levels of IL-6 in conjunction with IL-10 are associated with severe cases of COVID-19. Hence, it is possible that, in COVID-19 the induction of IL-10 solely serves to suppress adaptive immunity. Interestingly, through this function, IL-10 may help provide a supportive environment for the development of a cytokine storm, rather than facilitating its elimination. As a pleiotropic cytokine, IL-10 have also been shown to promote inflammatory cytokine production in autoimmune diseases and cancers [318,319]. Interestingly, blocking IL-10 activity have been reported to promote active proliferation and expansion of T cells in cancer patients, thus facilitate the resolution of the immunosuppression observed in these patients [319].

Further, as lymphocyte counts are considered reliable predictors of disease severity and mortality in COVID-19 patients, it is critical for SARS-CoV-2 infected patients to overcome lymphocyte suppression, especially with regard to their CD4 T cell counts. A previous study found that in a SARS-CoV infected mouse model, deletion of CD4 but not CD8 T cells lead to enhanced immune-mediated interstitial pneumonitis and delayed clearance of SARS-CoV from the lung [320]. This finding highlights the critical role of T cells, and especially CD4 T cells, in orchestrating adaptive immune responses following SARS-CoV infection. Further, infection of T cell deficient mice with murine coronavirus revealed that T cells temper early overactive innate responses and limit the cytokine storm observed following coronavirus infection [321]. Consistent with this finding, collective evidence indicates that viral clearance and T cell loss may lead to overactive innate immune responses during viral infections [308]. These observations strongly point to the importance of T cells not only to promote viral clearance, but also in limiting the pathological consequences of the cytokine storm. Further, animal models of chronic infection have been shown to reverse T cell exhaustion following IL-10 blockade [288,289]. Thus, as IL-10 may be responsible for this depression, either by inducing T cell reduction or exhaustion, it is possible that IL-10 blockade may serve as a potential therapeutic approach for COVID-19. It is possibly that by inhibiting IL-10, adaptive immune responses could facilitate the resolution of the cytokine storm through limiting the exaggerated innate immune response, and at the same time reduce the pathological levels of IL-6 produced by innate immune cells. It should be noted that the role of IL-10 in blocking the activity of IL-6 may be impaired in COVID-19 patients; however, further studies are needed to confirm this theory.

**Concluding remarks**

Review of currently available data indicate that IL-10 may be the main factor driving the immunosuppression observed following SARS-CoV-2 infection. Furthermore, in the case of COVID-19, the production of counterbalancing anti-inflammatory cytokines, specifically IL-10, may not function to limit the cytokine storm as previously thought, but rather enhance the pro-inflammatory environment in which a cytokine storm can develop. Based on these observations, immunomodulatory approaches for stimulating adaptive immunity, particularly CD4 T cells, through IL-10 blockade, have potential as a therapeutic approach for patients with COVID-19.
Acknowledgments

The authors would like to thank Professor Fahad J. Alshammary for his insight and critical advice during the preparation of this manuscript. The authors would also like to thank Dr Barbi A. Judd for her thoughtful and kind help in editing and proof-reading the final version of this manuscript.

Funding

The authors extend their appreciation to the Deanship for Research & Innovation, “Ministry of Education” in Saudi Arabia for funding this research work through the project number IFKSURP-106;

Data availability statement

The authors confirm that the data supporting the findings of this study are available within the article.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Author contributions

AFA was involved in analysis and interpretation of the data, literature search, figures generation and in drafting and revising the manuscript. AMA was involved in analysis and interpretation of the data discussed in the manuscript, and in revising the manuscript. All the authors have approved the final version of the manuscript.

ORCID

Amal F. Alshammary  http://orcid.org/0000-0002-2136-4001
Abdulrahman M. Al-Sulaiman  http://orcid.org/0000-0003-0186-8541

References

[1] Gorbalenya A, Baker S, Baric R, et al. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020;5(4):536–544.
[2] Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–733.
[3] WHO. Director-General’s opening remarks at the media briefing on COVID-19. Geneva, Switzerland: World Health Organization; (2020) March 11. [cited 26 Nov 2020]. [Available from: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19—11-march-2020]
[4] CSSE. Coronavirus COVID-19 Global Cases: the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU) (2020) [cited 2020 April 13]. Available from: https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6
[5] Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513.
[6] W-j G, Z- N, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–1720.
[7] Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.
[8] Chen C, Chen J, Huang J. Persistence of lymphocytopenia with CT abnormalities among patients with critical H7N9 swine-origin influenza A virus infection. Jpn J Radiol. 2015;33(10):657–662.
[9] Wang CH, Liu CY, Wan YL, et al. Persistence of lung inflammation and lung cytokines with high-resolution CT abnormalities during recovery from SARS. Respir Res. 2005;6(1):42.
[10] Chi Y, Zhu Y, Wen T, et al. Cytokine and chemokine levels in patients infected with the novel avian influenza A (H7N9) virus in China. J Infect Dis. 2013;208 (12):1962–1967.
[11] Pan M, Gao R, Lv Q, et al. Human infection with a novel, highly pathogenic avian influenza A (H5N6) virus: virological and clinical findings. J Infect. 2016;72 (1):52–59.
[12] Hui DS, Wong PC, Wang C. SARS: clinical features and diagnosis. Respirology. 2003;8(1):S20–4.
[13] Ko JH, Park GE, Lee JY, et al. Predictive factors for pneumonia development and progression to respiratory failure in MERS-CoV infected patients. J Infect. 2016;73(5):468–475.
[14] ENT. Loss of sense of smell as marker of COVID-19 infection. London, United Kingdom: Ear, Nose and Throat Surgery at The Royal College of Surgeons of England; (2020) March 21. [cited 28 March 2020]. [Available from: https://www.entuk.org/loss-sense-smell-marker-covid-19-infection-0]
[15] Bagheri SH, Asghari A, Farhadi M, et al. Coincidence of COVID-19 epidemic and olfactory dysfunction outbreak in Iran. Med J Islam Repub Iran. 2020;34:62.
[16] Kaye R, Chang CWD, Kazahaya K, et al. COVID-19 anosmia reporting tool: initial findings. Otolaryngol Head Neck Surg. 2020;163(1):132–134.
[17] Zheng F, Liao C, Fan QH, et al. Clinical characteristics of children with coronavirus disease 2019 in Hubei, China. Curr Med Sci. 2020;40(2):275–280.
[18] Hui DS, Madani EIA, Ta N, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis. 2020;91:264–266.
[19] Lee PI, Hsueh PR. Emerging threats from zoonotic coronaviruses-from SARS and MERS to 2019-nCoV. J Microbiol Immunol Infect. 2020;53(3):365–367.
[20] Riou J, Althaus CL. Pattern of early human-to-human transmission of Wuhan 2019 novel coronavirus (2019-nCoV), December 2019 to January 2020. Euro Surveill. 2020;25(4):2000058.

[21] Rothe C, Schunk M, Sothmann P, et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med. 2020;382(10):970–971.

[22] Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395(10223):514–523.

[23] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med. 2020;172(9):577–582.

[24] Wang Y, Wang Y, Chen Y, et al. Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures. J Med Virol. 2020;92(6):568–576.

[25] Liu Y, Gayle AA, Wilder-Smith A, et al. The reproductive number of COVID-19 is higher compared to SARS coronavirus. J Travel Med. 2020;27(2):taaa021.

[26] Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382(13):1199–1207.

[27] Wu JT, Leung K, Bushman M, et al. Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China. Nat Med. 2020;26(4):506–510.

[28] Zhao S, Lin Q, Ran J, et al. Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: a data-driven analysis in the early phase of the outbreak. Int J Infect Dis. 2020;92:214–217.

[29] Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–1069.

[30] Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475–481.

[31] Wei M, Yuan J, Liu Y, et al. Novel coronavirus infection in hospitalized infants under 1 year of age in China. JAMA. 2020;323(13):1313–1314.

[32] Chen F, Liu ZS, Zhang FR, et al. First case of severe childhood novel coronavirus pneumonia in China. Zhonghua Er Ke Za Zhi. 2020;58(3):179–182.

[33] WHO. Coronavirus disease 2019 (COVID-19): situation report, 57. Geneva, Switzerland: World Health Organization; (2020) March 17. [cited 15 Oct 2020]. [Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200317-sitrep-57-covid-19.pdf?sfvrsn=a26922f2_2]

[34] Xie J, Tong Z, Guan X, et al. Clinical characteristics of patients who died of coronavirus disease 2019 in China. JAMA Network Open. 2020;3(4):e205619.

[35] Chen H, Guo J, Wang C, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet. 2020;395(10226):809–815.

[36] Schwartz DA. An analysis of 38 pregnant women with COVID-19, their newborn infants, and maternal-fetal transmission of SARS-CoV-2: maternal coronavirus infections and pregnancy outcomes. Arch Pathol Lab Med. 2020;144(7):799–805.

[37] Liu Y, Chen H, Tang K, et al. Clinical manifestations and outcome of SARS-CoV-2 infection during pregnancy. J Infect. 2020. DOI:10.1016/j.jinf.2020.02.028

[38] Liu D, Li L, Wu X, et al. Pregnancy and Perinatal Outcomes of Women With Coronavirus Disease (COVID-19) Pneumonia: a Preliminary Analysis. AJR Am J Roentgenol. 2020;215(1):127–132.

[39] Oakes MC, Kernberg AS, Carter EB, et al. Pregnancy as a risk factor for severe coronavirus disease 2019 using standardized clinical criteria. Am J Obstet Gynecol MFM. 2021;3(3):100319. DOI:10.1016/j.ajogmf.2021.100319.

[40] Zambrano LD, Ellington S, Strid P, et al. Update: characteristics of Symptomatic Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status — united States, January 22–October 3, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(44):1641–1647.

[41] Khalil A, Kalafat E, Benlioglu C, et al. SARS-CoV-2 infection in pregnancy: a systematic review and meta-analysis of clinical features and pregnancy outcomes. EClinicalMedicine. 2020;25:100446.

[42] Paraskevis D, Kostaki EG, Magiorkinis G, et al. Full-genome evolutionary analysis of the novel coronavirus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event. Infect Genet Evol. 2020;79:104121.

[43] Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol. 2015;1282:1–23.

[44] Song Z, Xu Y, Bao L, et al. From SARS to MERS, Thrusting Coronaviruses into the Spotlight. Viruses. 2019;11(1):59.

[45] Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579(7798):265–269.

[46] Jackson RJ, Hellen CU, Pestova TV. The mechanism of eukaryotic translation initiation and principles of its regulation. Nat Rev Mol Cell Biol. 2010;11(2):113–127.

[47] Brierley I, Digard P, Inglis SC. Characterization of an efficient coronavirus ribosomal frameshifting signal: requirement for an RNA pseudoknot. Cell. 1989;57(4):537–547.

[48] De Wilde AH, Snijder EJ, Kikkert M, et al. Host factors in coronavirus replication. Curr Top Microbiol Immunol. 2018;419:1–42.

[49] Sola I, Almazán F, Zúñiga S, et al. Continuous and discontinuous RNA synthesis in coronaviruses. Annu Rev Virol. 2015;2(1):265–288.

[50] Snijder EJ, Decroly E, Ziebuhr J. The nonstructural proteins directing coronavirus RNA synthesis and processing. Adv Virus Res. 2016;95:59–126.

[51] Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019;17(3):181–192.

[52] Guo YR, Cao QD, Hong ZS, et al. The origin, transmission and clinical therapies on coronavirus disease
2019 (COVID-19) outbreak - an update on the status. Mil Med Res. 2020;7(1):11.

[53] Delmas B, Laude H. Assembly of coronavirus spike protein into trimers and its role in epitope expression. J Virol. 1990;64(11):5367–5375.

[54] Beniac DR, Andonov A, Grudeski E, et al. Architecture of the SARS coronavirus prefusion spike. Nat Struct Mol Biol. 2006;13(8):751–752.

[55] Hulswit RJ, De Haan CA, Bosch BJ. Coronavirus spike protein and tropism changes. Adv Virus Res. 2016;96:29–57.

[56] Neuman BW, Kiss G, Kunding AH, et al. A structural analysis of M protein in coronavirus assembly and morphology. J Struct Biol. 2011;174(1):11–22.

[57] Armstrong J, Niemann H, Smeekens S, et al. Sequence and topology of a model intracellular membrane protein, E1 glycoprotein, from a coronavirus. Nature. 1984;308(5961):751–752.

[58] DeDiego ML, Alvarez E, Almazán F, et al. A severe acute respiratory syndrome coronavirus that lacks the E gene is attenuated in vitro and in vivo. J Virol. 2007;81(4):1701–1713.

[59] Nieto-Torres JL, DeDiego ML, Verdiá-Báguena C, et al. Severe acute respiratory syndrome coronavirus envelope- protein ion channel activity promotes virus fitness and pathogenesis. PLoS Pathog. 2014;10(5):e1004077.

[60] Chang CK, Sue SC, Yu TH, et al. Modular organization of SARS coronavirus nucleocapsid protein. J Biomed Sci. 2006;13(1):59–72.

[61] Hurst KR, Koetzner CA, Masters PS. Identification of in vivo-interacting domains of the murine coronavirus nucleocapsid protein. J Virol. 2009;83(14):7221–7234.

[62] Kuo L, Masters PS. Functional analysis of the murine coronavirus genomic RNA packaging signal. J Virol. 2013;87(9):5182–5192.

[63] Zhao L, Jha BK, Wu A, et al. Antagonism of the interferon-induced OAS-RNase L pathway by murine coronavirus ns2 protein is required for virus replication and liver pathology. Cell Host Microbe. 2012;11(6):607–616.

[64] Hagemeijer MC, Rottier PJ, De Haan CA. Biogenesis and dynamics of the coronavirus replicative structures. Viruses. 2012;4(11):3245–3269.

[65] BioRender. (2021). [cited 3 Sep 2020]. [Available from: https://biorender.com/]

[66] Chan JF, Kok KH, Zhu Z, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 2020;9(1):221–236.

[67] Jia HP, Look DC, Shi L, et al. ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia. J Virol. 2005;79(23):14614–14621.

[68] Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426(6965):450–454.

[69] Li W, Zhang C, Sui J, et al. Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2. EMBO J. 2005;24(8):1634–1643.

[70] Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–273.

[71] Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol. 2020;5(4):562–569.

[72] Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 andTMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2):271–80e8.

[73] Wan Y, Shang J, Graham R, et al. Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus. J Virol. 2020;94(7):e00127–20.

[74] Shirato K, Kawase M, Matsuyama S. Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2. J Virol. 2013;87(23):12552–12561.

[75] Burkard C, Verheije MH, Wicht O, et al. Coronavirus cell entry occurs through the endo-/lysosomal pathway in a proteolysis-dependent manner. PLoS Pathog. 2014;10(11):e1004502.

[76] Yang Y, Du L, Liu C, et al. Receptor usage and cell entry of bat coronavirus HKU4 provide insight into bat-to-human transmission of MERS coronavirus. PNAS. 2014;111(34):12516–12521.

[77] Raj VS, Mou H, Smits SL, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature. 2013;495(7440):251–254.

[78] Ou X, Liu Y, Lei X, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun. 2020;11(1):1620.

[79] Zhou T, Tsybovsky Y, Gorman J, et al. Cryo-EM Structures of SARS-CoV-2 Spike without and with ACE2. Reveal a pH-Dependent Switch to Mediate Endosomal Positioning of Receptor-Binding Domains. Cell Host Microbe. 2020;28(6):867–79.e5.

[80] Huang IC, Bosch BJ, Li F, et al. SARS coronavirus, but not human coronavirus NL63, utilizes cathepsin L to infect ACE2-expressing cells. J Biol Chem. 2006;281(6):3198–3203.

[81] Simmons G, Gosalia DN, Rennekamp AJ, et al. Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. PNAS. 2005;102(33):11876–11881.

[82] Stertz S, Reichelt M, Spiegel M, et al. The intracellular sites of early replication and budding of SARS-coronavirus. Virology. 2007;361(2):304–315.

[83] Ulasli M, Verheije MH, De Haan CA, et al. Qualitative and quantitative ultrastructural analysis of the membrane rearrangements induced by coronavirus. Cell Microbiol. 2010;12(6):844–861.

[84] Maier HJ, Hawes PC, Cottam EM, et al. Infectious bronchitis virus generates spherules from zippered endoplasmic reticulum membranes. mBio. 2013;4(5):e00801–13.

[85] Gosert R, Kanjanahaluethai A, Egger D, et al. RNA replication of mouse hepatitis virus takes place at double-membrane vesicles. J Virol. 2002;76(8):3697–3708.

[86] Knoops K, Kikkert M, Worm SH, et al. SARS-coronavirus replication is supported by a reticulovesicular network of modified endoplasmic reticulum. PLoS Biol. 2008;6(9):e226.
[87] Goldsmith CS, Tatti KM, Ksiazek TG, et al. Ultrastructural characterization of SARS coronavirus. Emerg Infect Dis. 2004;10(2):320–326.

[88] Tooze J, Tooze SA, Fuller SD. Sorting of progeny coronavirus from condensed secretory proteins at the exit from the trans-Golgi network of A/22.T cells. J Cell Biol. 1987;105(3):1215–1226.

[89] Tooze J, Tooze S, Warren G. Replication of coronavirus MHV–A59 in sac-cells: determination of the first site of budding of progeny virions. Eur J Cell Biol. 1984;33(2):281–293.

[90] Bost AG, Carnahan RH, Lu XT, et al. Four proteins processed from the replicase gene polyprotein of mouse hepatitis virus colocalize in the cell periphery and adjacent to sites of virosp assembly. J Virol. 2000;74(7):3379–3387.

[91] Bost AG, Prentice E, Denison MR. Mouse hepatitis virus replicase protein complexes are translocated to sites of M protein accumulation in the ERGIC at late times of infection. Virology. 2001;285(1):21–29.

[92] Klumperman J, Locker JK, Meijer A, et al. Coronavirus M proteins accumulate in the Golgi complex beyond the site of virosp budding. J Virol. 1994;68(10):6523–6534.

[93] Hagemeijer MC, Monastyrskra I, Griffith J, et al. Membrane rearrangements mediated by coronavirus nonstructural proteins 3 and 4. Virology. 2014;458-459:125–135.

[94] Molenkamp R, Spaan WJ. Identification of a specific interaction between the coronavirus mouse hepatitis virus A59 nucleocapsid protein and packaging signal. Virology. 1997;239(1):78–86.

[95] De Haan CA, Rottier PJ. Molecular interactions in the assembly of coronaviruses. Adv Virus Res. 2005;64:165–203.

[96] Van Der Hoeven B, Oudshoorn D, Koster AJ, et al. Biogenesis and architecture of arterivirus replication organelles. Virus Res. 2016;220:70–90.

[97] Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10299):1033–1034.

[98] Nicholls JM, Poon LL, Lee KC, et al. Lung pathology of fatal severe acute respiratory syndrome. Lancet. 2003;361(9371):1773–1778.

[99] Gu J, Gong E, Zhan B, et al. Multiple organ infection and the pathogenesis of SARS. J Exp Med. 2005;202(3):415–424.

[100] Van Den Brand JM, Haagmans BL, Van Riel D, et al. The pathology and pathogenesis of experimental severe acute respiratory syndrome and influenza in animal models. J Comp Pathol. 2014;151(1):83–112.

[101] Sims AC, Baric RS, Yount B, et al. Severe acute respiratory syndrome coronavirus infection of human ciliated airway epithelia: role of ciliated cells in viral spread in the conducting airways of the lungs. J Virol. 2005;79(24):15511–15524.

[102] Franks TJ, Chong PY, Chui P, et al. Lung pathology of severe acute respiratory syndrome (SARS): a study of 8 autopsy cases from Singapore. Hum Pathol. 2003;34(8):743–748.

[103] Hotchkiss RS, Swanson PE, Freeman BD, et al. Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit Care Med. 1999;27(7):1230–1251.

[104] Hotchkiss RS, Nicholson DW. Apoptosis and caspases regulate death and inflammation in sepsis. Nat Rev Immunol. 2006;6(11):813–822.

[105] Chang KC, Unsinger J, Davis CG, et al. Multiple triggers of cell death in sepsis: death receptor and mitochondrial-mediated apoptosis. FASEB J. 2007;21(3):708–719.

[106] Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell. 2010;140(6):805–820.

[107] Bryant CE, Gay NJ, Heymans S, et al. Advances in Toll-like receptor biology: modes of activation by diverse stimuli. Crit Rev Biochem Mol Biol. 2015;50(5):359–379.

[108] Creagh EM, O’Neill LA. TLRs, NLRs and RLRs: a trinity of pathogen sensors that co-operate in innate immunity. Trends Immunol. 2006;27(8):352–357.

[109] Janeway CA Jr.. Approaching the asymptote? Evolution and revolution in immunity. Cold Spring Harb Symp Quant Biol. 1989;54:1–13.

[110] Hecker G, Redecke V, Hecker H. Activation of the immune system by bacterial CpG-DNA. Immunology. 2002;105(3):245–251.

[111] Joosten LA, Abdollahi-Roodsaz S, Dinarello CA, et al. Toll-like receptors and chronic inflammation in rheumatic diseases: new developments. Nat Rev Rheumatol. 2016;12(6):344–357.

[112] Relja B, Land WG. Damage-associated molecular patterns in trauma. Eur J Trauma Emerg Surg. 2019;46(4):751–775.

[113] Wutzler S, Lustenberger T, Relja B, et al. Pathophysiology of multiple trauma: intensive care medicine and timing of treatment. Chrirurg. 2013;84(9):753–758.

[114] Medzhitov R. Approaching the asymptote: 20 years later. Immunity. 2009;30(6):766–775.

[115] Rubartelli A, Lotze MT. Inside, outside, upside down: damage-associated molecular-pattern molecules (DAMPs) and redox. Trends Immunol. 2007;28(10):429–436.

[116] Muruve DA, Petrillo V, Zaiss AK, et al. The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response. Nature. 2008;452(7183):103–107.

[117] Keel M, Trentz O. Pathophysiology of polytrauma. Injury. 2005;36(5):691–709.

[118] Poltorak A, He X, Smirnova I, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science. 1998;282(5396):2085–2088.

[119] Namas RA, Vodovotz Y, Almahmoud K, et al. Temporal patterns of circulating inflammation biomarker networks differentiate susceptibility to nosocomial infection following blunt trauma in humans. Ann Surg. 2016;263(1):191–198.

[120] Huber-Lang M, Lambris JD, Ward PA. Innate immune responses to trauma. Nat Immunol. 2018;19(4):327–341.

[121] Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol. 2007;81(1):1–5.
[122] Zedler S, Faist E. The impact of endogenous triggers on trauma-associated inflammation. Curr Opin Crit Care. 2006;12(6):595–601.

[123] Manson J, Thierrermann C, Brohi K. Trauma alarmins as activators of damage-induced inflammation. Br J Surg. 2012;99(Suppl 1):12–20.

[124] Relja B, Mörs K, Marzi I. Danger signals in trauma. Eur J Trauma Emerg Surg. 2018;44(3):301–316.

[125] Osuka A, Ogura H, Ueyama M, et al. Immune response to traumatic injury: harmony and discordance of immune system homeostasis. Acute Med Surg. 2014;1(2):63–69.

[126] Maung AA, Fujimi S, MacConnara MP, et al. Injury enhances resistance to Escherichia coli infection by boosting innate immune system function. J Immunol. 2008;180(4):2450–2458.

[127] Southard R, Ghosh S, Hilliard J, et al. Pulmonary conduction is associated with toll-like receptor 4 upregulation and decreased susceptibility to pseudomonas pneumonia in a mouse model. Shock. 2012;37(6):629–633.

[128] Grossman JA, Adams JP, Kunec J. Prophylactic antibiotics in simple hand lacerations. JAMA. 1981;245(10):1055–1056.

[129] Sauaia A, Moore FA, Moore EE, et al. Early risk factors for postinjury multiple organ failure. World J Surg. 1996;20(4):392–400.

[130] Bone RC. Immunologic dissonance: a continuing evolution in our understanding of the systemic inflammatory response syndrome (SIRS) and the multiple organ dysfunction syndrome (MODS). Ann Intern Med. 1996;125(8):680–687.

[131] Bone RC, Newton SI. sepsis, SIRS, and CARS. Crit Care Med. 1996;24(7):1125–1128.

[132] Osuchowski MF, Welch K, Siddiqui J, et al. Circulating cytokine/inhibitor profiles reshape the understanding of the SIRS/CARS continuum in sepsis and predict mortality. J Immunol. 2006;177(3):1967–1974.

[133] Xiao W, Mindrinos MN, Seok J, et al. An genomic storm in critically injured humans. J Exp Med. 2011;208(13):2581–2590.

[134] Sands KE, Bates DW, Lanken PN, et al. Epidemiology of sepsis syndrome in 8 academic medical centers. JAMA. 1997;278(3):234–240. DOI:10.1001/jama.1997.03550030074038.

[135] Paterson HM, Murphy TJ, Purcell EJ, et al. Injury primes the innate immune system for enhanced Toll-like receptor reactivity. J Immunol. 2003;171(3):1473–1483.

[136] Zang Y, Dolan SM, Ni Choileain N, et al. Burn injury initiates a shift in superantigen-induced T cell responses and host survival. J Immunol. 2004;172(8):4883–4892.

[137] Fan J, Li Y, Levy RM, et al. Hemorrhagic shock induces NAD(P)H oxidase activation in neutrophils: role of HMGB1-TLR4 signaling. J Immunol. 2007;178(10):6573–6580.

[138] Faist E, Schinkel G, Zimmer S. Update on the mechanisms of immune suppression of injury and immune modulation. World J Surg. 1996;20(4):454–459.

[139] Fan J, Kapus A, Li YH, et al. Priming for enhanced alveolar fibrin deposition after hemorrhagic shock: role of tumor necrosis factor. Am J Respir Cell Mol Biol. 2000;22(4):412–421.

[140] Rose S, Marzi I. Mediators in polytrauma–pathophysiological significance and clinical relevance. Langenbecks Arch Surg. 1998;383(3–4):199–208.

[141] Wafaísade A, Lefering R, Bouillon B, et al. Epidemiology and risk factors of sepsis after multiple trauma: an analysis of 29,829 patients from the Trauma Registry of the German Society for Trauma Surgery. Crit Care Med. 2011;39(4):621–628.

[142] Riches DWH, Martin TR. Overview of Innate Lung Immunity and Inflammation. Methods Mol Biol. 2018;1809:17–30.

[143] Whitsett JA, Alenghat T. Respiratory epithelial cells orchestrate pulmonary innate immunity. Nat Immunol. 2015;16(1):27–35.

[144] Antunes MB, Cohen NA. Mucociliary clearance—a critical upper airway host defense mechanism and methods of assessment. Curr Opin Allergy Clin Immunol. 2007;7(1):5–10.

[145] Janssen WJ, Bratton DL, Jakubzick CV, et al. Myeloid cell turnover and clearance. Microbiol Spectr. 2016;4(6):10.

[146] Platz J, Beisswenger C, Dalpke A, et al. Microbial DNA induces a host defense reaction of human respiratory epithelial cells. J Immunol. 2004;173(2):1219–1223.

[147] Karampitsakos T, Woolard T, Bouros D, et al. Toll-like receptors in the pathogenesis of pulmonary fibrosis. Eur J Pharmacol. 2017;808:35–43.

[148] Droemann D, Goldmann T, Branscheid D, et al. Toll-like receptor 2 is expressed by alveolar epithelial cells type II and macrophages in the human lung. Histochem Cell Biol. 2003;119(2):103–108.

[149] Vermaelen K, Pauwels R. Accurate and simple discrimination of mouse pulmonary dendritic cell and macrophage populations by flow cytometry: methodology and new insights. Cytometry A. 2004;61A(2):170–177.

[150] Van Rijt LS, Jung S, Kleinjan A, et al. In vivo depletion of lung CD11c+ dendritic cells during allergen challenge abrogates the characteristic features of asthma. J Exp Med. 2005;201(6):981–991.

[151] Lin KL, Suzuki Y, Nakano H, et al. CCR2+ monocyte-derived dendritic cells and exudate macrophages produce influenza-induced pulmonary immune pathology and mortality. J Immunol. 2008;180(4):2562–2572.

[152] Gwyer TD, Woolard T. Macrophage-mediated inflammation and disease: a focus on the lung. Mediators Inflamm. 2012(2012):140937.

[153] Knapp S, Leemans JC, Florquin S, et al. Alveolar macrophages have a protective antiinflammatory role during murine pneumococal pneumonia. Am J Respir Crit Care Med. 2003;167(2):171–179.

[154] Serbina NV, Jia T, Hohl TM, et al. Monocyte-mediated defense against microbial pathogens. Annu Rev Immunol. 2008;26(1):421–452.

[155] Goldstein E, Lippert W, Warshauer D. Pulmonary alveolar macrophage. Defender against bacterial infection of the lung. J Clin Invest. 1974;54(3):519–528.
[156] Wynn TA. Integrating mechanisms of pulmonary fibrosis. J Exp Med. 2011;208(7):1339–1350.

[157] Selman M, Pardo A. The epithelial/fibroblastic pathway in the pathogenesis of idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol. 2003;29(3 Suppl):S93–7.

[158] Tang YW, Johnson JE, Browning PJ, Cruz-Gervis RA, Davis A, Graham BS, et al. Herpesvirus DNA is consistently detected in lungs of patients with idiopathic pulmonary fibrosis. J Clin Microbiol. 2003;41(6):2633–2640. DOI:10.1128/jcm.41.6.2633-2640.2003.

[159] Mora AL, Torres-González E, Rojas M, et al. Activation of alveolar macrophages via the alternative pathway in herpesvirus-induced lung fibrosis. Am J Respir Cell Mol Biol. 2006;35(4):466–473.

[160] Blumenthal RL, Campbell DE, Hwang P, et al. Human alveolar macrophages induce functional inactivation in antigen-specific CD4 T cells. J Allergy Clin Immunol. 2001;107(2):258–264.

[161] Chanteux H, Guisset AC, Pilette C, et al. LPS induces IL-10 production by human alveolar macrophages via MAPKinases- and Sp1-dependent mechanisms. Respir Res. 2007;8(1):71.

[162] Holt PG, Oliver J, Bilyk N, et al. Downregulation of the antigen presenting cell function(s) of pulmonary dendritic cells in vivo by resident alveolar macrophages. J Exp Med. 1993;177(2):397–407.

[163] Hussell T, Bell TJ. Alveolar macrophages: plasticity in a tissue-specific context. Nat Rev Immunol. 2014;14(2):81–93.

[164] Byrne AJ, Mathie SA, Gregory LG, et al. Pulmonary macrophages: key players in the innate defence of the airways. Thorax. 2015;70(12):1189–1196.

[165] Garbi N, Lambrecht BN. Location, function, and ontogeny of pulmonary macrophages during the steady state. Pflugers Arch. 2017;469(3-4):561–572.

[166] Munger JS, Huang X, Kawakatsu H, et al. The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell. 1999;96(3):319–328.

[167] Morris DG, Huang X, Kaminiski N, et al. Loss of integrin alpha(v)beta6-mediated TGF-beta activation causes Mmp12-dependent emphysema. Nature. 2003;422(6928):169–173.

[168] Soltys J, Bonfield T, Chmiel J, et al. IL-10 deficiency in the lung of cystic fibrosis (cftr(-/-)) and IL-10 knockout mice causes increased expression and function of B7 costimulatory molecules on alveolar macrophages. J Immunol. 2002;168(4):1903–1910.

[169] Gardai SJ, Xiao YQ, Dickinson M, et al. By binding SIRPalpha or calreticulin/CD91, lung collectins act as dual function surveillance molecules to suppress or enhance inflammation. Cell. 2003;115(1):13–23.

[170] Janssen WJ, McPhillips KA, Dickinson MG, et al. Surfactant proteins A and D suppress alveolar macrophage phagocytosis via interaction with SIRP alpha. Am J Respir Crit Care Med. 2008;178(2):158–167.

[171] Dawson TC, Beck MA, Kuziel WA, et al. Contrasting effects of CCR5 and CCR2 deficiency in the pulmonary inflammatory response to influenza A virus. Am J Pathol. 2000;156(6):1951–1959.

[172] Herold S, Steinmueller M, Von Wulffen W, et al. Lung epithelial apoptosis in influenza virus pneumonia: the role of macrophage-expressed TNF-related apoptosis-inducing ligand. J Exp Med. 2008;205(13):3065–3077.

[173] Narasaraju T, Ng HH, Phoon MC, et al. Antibody treatment enhances damage and impedes repair of the alveolar epithelium in influenza pneumonia. Am J Respir Cell Mol Biol. 2010;42(6):732–743.

[174] Yen Y-T, Liao F, Hsiao C-H, et al. Modeling the early events of severe acute respiratory syndrome coronavirus infection in vitro. J Virol. 2006;80(6):2684–2693.

[175] Cherry JD. The chronology of the 2002-2003 SARS mini pandemic. Paediatr Respir Rev. 2004;5(4):262–269.

[176] Tonturi AL, Whitmore A, Agnihothram S, et al. Toll-like receptor 3 signaling via TRIF contributes to a protective innate immune response to severe acute respiratory syndrome coronavirus infection. mBio. 2015;6(3):e00638–15.

[177] Jimenez-Guareño JM, Nieto-Torres JL, DeDiego ML, et al. The PDZ-binding motif of severe acute respiratory syndrome coronavirus envelope protein is a determinant of viral pathogenesis. PLoS Pathog. 2014;10(8):e1004320.

[178] Nieto-Torres JL, Verdiá-Báguena C, Jimenez-Guareño JM, et al. Severe acute respiratory syndrome coronavirus E protein transports calcium ions and activates the NLRP3 inflammasome. Virology. 2015;485:330–339.

[179] Jahnson FL, Strickland DH, Thomas JA, et al. Accelerated antigen sampling and transport by airway mucosal dendritic cells following inhalation of a bacterial stimulus. J Immunol. 2006;177(9):5861–5867.

[180] Lambrecht BN, Hammad H. Lung dendritic cells in respiratory viral infection and asthma: from protection to immunopathology. Annu Rev Immunol. 2012;30(1):243–270.

[181] Niess JH, Brand S, Gu X, et al. CX3CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearance. Science. 2005;307(5707):254–258.

[182] Rescigno M, Urbano M, Valzasina B, et al. Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat Immunol. 2001;2(4):361–367.

[183] Huh JC, Strickland DH, Jahnson FL, et al. Bidirectional interactions between antigen-bearing respiratory tract dendritic cells (DCs) and T cells precede the late phase reaction in experimental asthma: DC activation occurs in the airway mucosa but not in the lung parenchyma. J Exp Med. 2003;198(1):19–30.

[184] Vermaelen KY, Carro-Muino I, Lambrecht BN, et al. Specific migratory dendritic cells rapidly transport antigen from the airways to the thoracic lymph nodes. J Exp Med. 2001;193(1):51–60.

[185] GeurtsvanKessel CH, Willart MA, Van Rijt LS, et al. Clearance of influenza virus from the lung depends on migratory langerin+CD11b− but not plasmacytoid dendritic cells. J Exp Med. 2008;205(7):1621–1634.

[186] Desch AN, Randolph GJ, Murphy K, et al. CD103+ pulmonary dendritic cells preferentially acquire and present apoptotic cell-associated antigen. J Exp Med. 2011;208(9):1789–1797.
[187] Reibman J, Hsu Y, Chen LC, et al. Airway epithelial cells release MIP-3alpha/CCL20 in response to cyto-
kines and ambient particulate matter. Am J Respir Cell Mol Biol. 2003;28(6):648–654.

[188] Lajoie S, Lewkowich IP, Suzuki Y, et al. Complement-
mediated regulation of the IL-17A axis is a central genetic determinant of the severity of experimental allergic asthma. Nat Immunol. 2010;11(10):928–935.

[189] Lewkowich IP, Lajoie S, Clark JR, et al. Allergen uptake, activation, and IL-23 production by pulmonary myeloid DCs drives airway hyperresponsiveness in asthma-susceptible mice. PLoS One. 2008;3(12):e3879.

[190] Stumbles PA, Thomas JA, Pimm CL, et al. Resting respiratory tract dendritic cells preferentially stimulate Th2 helper cell type 2 (Th2) responses and require oblig-
atory cytokine signals for induction of TH1 immunity. J Exp Med. 1998;188(11):2019–2031.

[191] McMenamin C, Holt PG. The natural immune response to inhaled soluble protein antigens involves major histocompatibility complex (MHC) class I-restricted CD8+ T cell-mediated but MHC class II-restricted CD4+ T cell-dependent immune deviation resulting in selective suppression of immunoglobulin E production. J Exp Med. 1993;178(3):889–899.

[192] Hoyne GF, Askonas BA, Hetzel C, et al. Regulation of house dust mite responses by intranasally administered peptide: transient activation of CD4+ T cells precedes the development of tolerance in vivo. Int Immunol. 1996;8(3):335–342.

[193] Howard CJ, Hope JC, Stephens SA, et al. Co-stimulation and modulation of the ensuing immune response. Vet Immunol Immunopathol. 2002;87(3–4):123–130.

[194] Narasaraju T, Yang E, Samy RP, et al. Excessive neutrophils and neutrophil extracellular traps contribute to acute lung injury of influenza pneumonia. Am J Pathol. 2011;179(1):199–210.

[195] Tate MD, Deng YM, Jones JE, Anderson GP, Brooks AG, Reading PC. Neutrophils ameliorate lung injury and the development of severe disease during influenza infection. J Immunol. 2009;183(11):7441–7450. DOI:10.4049/jimmunol.0902497.

[196] Teijaro JR, Walsh KB, Cahalan S, et al. Endothelial cells are central orchestrators of cytokine amplification during influ-
enza virus infection. Cell. 2011;146(6):980–991.

[197] Tak T, Tesselaar K, Pillay J, et al. What’s your age again? Determination of human neutrophil half-lives revisited. J Leukoc Biol. 2013;94(4):595–601.

[198] Pillay J, Den Braber I, Vriskeoop N, et al. In vivo labeling with 2H2O reveals a human neutrophil life-
span of 5.4 days. Blood. 2010;116(4):625–627.

[199] Tamayo E, Gómez E, Bustamante J, et al. Evolution of neutrophil apoptosis in septic shock survivors and nonsurvivors. J Crit Care. 2012;27(4):415.e1–11.

[200] Jorgensen I, Rayamajhi M, Miao EA. Programmed cell death as a defence against infection. Nat Rev Immunol. 2017;17(3):151–164.

[201] Paunel-Görgülü A, Kirichevska T, Lögters T, et al. Molecular mechanisms underlying delayed apoptosis in neutrophils from multiple trauma patients with and without sepsis. Mol Med. 2012;18(3):325–335.

[202] Ayala A, Chung CS, Lomas JL, et al. Shock-induced neutrophil mediated priming for acute lung injury in mice: divergent effects of TLR-4 and TLR-4/FasL deficiency. Am J Pathol. 2002;161(6):2283–2294.

[203] Matute-Bello G, Liles WC, Radella F 2nd, et al. Modulation of neutrophil apoptosis by granulocyte colony-stimulating factor and granulocyte/macrophage colony-stimulating factor during the course of acute respiratory distress syndrome. Crit Care Med. 2000;28(1):1–7.

[204] Drife G, Dunn-Sigrist I, Tissiéres P, et al. Innate immune functions of immature neutrophils in patients with sepsis and severe systemic inflam-
matory response syndrome. Crit Care Med. 2013;41(3):820–832.

[205] Nathan C. Neutrophils and immunity: challenges and opportunities. Nat Rev Immunol. 2006;6(3):173–182.

[206] Cowburn AS, Condiffe AM, Farahi N, et al. Advances in neutrophil biology: clinical implications. Chest. 2008;134(3):606–612.

[207] Sittipunt C, Steinberg KP, Ruzinski JT, et al. Nitric oxide and nitrotyrosine in the lungs of patients with acute respiratory distress syndrome. Am J Respir Crit Care Med. 2001;163(2):503–510.

[208] MacLean JA, Xia W, Pinto CE, et al. Sequestration of inhaled particulate antigens by lung phagocytes. A mechanism for the effective inhibition of pulmonary cell-mediated immunity. Am J Pathol. 1996;148(2):657–666.

[209] Jorch SK, Kubes P. An emerging role for neutrophil extracellular traps in noninfectious disease. Nat Med. 2017;23(3):279–287.

[210] Grommes J, Soehnlein O. Contribution of neutrophils to acute lung injury. Mol Med. 2011;17(3–4):293–307.

[211] Misharin AV, Morales-Nebreda L, Mutlu GM, et al. Flow cytometric analysis of macrophages and dendritic cell subsets in the mouse lung. Am J Respir Cell Mol Biol. 2013;49(4):503–510.

[212] Murphy BS, Bush HM, Sundareshan V, et al. Characterization of macrophage activation states in patients with cystic fibrosis. J Cyst Fibros. 2010;9(5):314–322.

[213] Niesler U, Palmer A, Radermacher P, et al. Role of alveolar macrophages in the inflammatory response after trauma. Shock. 2014;42(1):3–10.

[214] Robb CT, Regan KH, Dorward DA, et al. Key mechan-
isms governing resolution of lung inflammation. Semin Immunopathol. 2016;38(4):425–448.

[215] Bonfield TL, Panuska JR, Konstan MW, et al. Inflammatory cytokines in cystic fibrosis lungs. Am J Respir Crit Care Med. 1995;152(6):2111–2118.

[216] Palfreyman RW, Watson ML, Eden C, et al. Induction of biologically active interleukin-8 from lung epithelial cells by Burkholderia (Pseudomonas) cepacia products. Infect Immun. 1997;65(2):617–622.

[217] De Soya A, Ellis CD, Khan CM, et al. Demarco de Hormaeche R. Burkholderia cepacia lipopolysac-
charide, lipid A, and proinflammatory activity. Am J Respir Crit Care Med. 2004;170(1):70–77.
[218] Kopp BT, Abdulrahman BA, Khweek AA, et al. Exaggerated inflammatory responses mediated by Burkholderia cenocepacia in human macrophages derived from Cystic fibrosis patients. Biochem Biophys Res Commun. 2012;424(2):221–227.

[219] Chan PK, To KF, Lo AW, et al. Persistent infection of SARS coronavirus in colonic cells in vitro. J Med Virol. 2004;74(1):1–7.

[220] Chen W, Yan M, Yang L, et al. SARS-associated coronavirus transmitted from human to pig. Emerg Infect Dis. 2005;11(3):446–448.

[221] Baric RS, Yount B. Subgenomic negative-strand RNA function during mouse hepatitis virus infection. J Virol. 2000;74(9):4039–4046.

[222] Cavanagh D. Nidovirales: a new order comprising Coronaviridae and Arterviridae. Arch Virol. 1997;142(3):629–633.

[223] Channappanavar R, Fehr AR, Vijay R, et al. Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice. Cell Host Microbe. 2016;19(2):181–193.

[224] Kotrange S, Kopp B, Akther A, et al. Burkholderia cenocepacia O polysaccharide chain contributes to caspase-1-dependent IL-1βeta production in macrophages. J Leukoc Biol. 2011;89(3):481–488.

[225] Cremer TJ, Shah P, Cornel-Thuycke E, et al. Akt-mediated proinflammatory response of mononuclear phagocytes infected with Burkholderia cenocepacia occurs by a novel GSK3β-dependent, IkB kinase-independent mechanism. J Immunol. 2011;187(2):635–643.

[226] Abraham SN, St John AL. Mast cell-orchestrated immunity to pathogens. Nat Rev Immunol. 2010;10(6):440–452.

[227] Piliponsky AM, Acharya M, Shubin NJ. Mast cells in viral, bacterial, and fungal infection immunity. Int J Mol Sci. 2019;20(12):2851.

[228] Sayed BA, Christy A, Quirion MR, et al. The master switch: the role of mast cells in autoimmunity and tolerance. Annu Rev Immunol. 2008;26(1):705–739.

[229] Wang Z, Lai Y, Bernard JJ, et al. Skin mast cells protect mice against vaccinia virus by triggering mast cell receptor S1PR2 and releasing antimicrobial peptides. J Immunol. 2012;188(4):345–357.

[230] Gurish MF, Austen KF. Developmental origin and functional specialization of mast cell subsets. Immunity. 2012;37(1):25–33.

[231] Wernersson S, Pejler G. Mast cell secretory granules: armed for battle. Nat Rev Immunol. 2014;14(7):478–494.

[232] Galli SJ, Tsai M. IgE and mast cells in allergic disease. Nat Med. 2012;18(5):693–704.

[233] Boyce JA. Mast cells and eicosanoid mediators: a system of reciprocal paracrine and autocrine regulation. Immunol Rev. 2007;217(1):168–185.

[234] Deitch EA, Landry KN, McDonald JC. Postburn impaired cell-mediated immunity may not be due to lazy lymphocytes but to overwork. Ann Surg. 1985;201(6):793–802.

[235] Murphy TJ, Ni Choileain N, Zang Y, et al. CD4+CD25 + regulatory T cells control inactive immune reactivity after injury. J Immunol. 2005;174(5):2957–2963.

[236] Lomas-Niera JL, Perl M, Chung CS, et al. Shock and hemorrhage: an overview of animal models. Shock. 2005;24(Suppl Supplement 1):33–39.

[237] Venet F, Chung CS, Monneret G, et al. Regulatory T cell populations in sepsis and trauma. J Leukoc Biol. 2008;83(3):523–535.

[238] Cheadle WG, Pemberton RM, Robinson D, et al. Lymphocyte subset responses to trauma and sepsis. J Trauma. 1993;35(6):844–849.

[239] Puyana JC, Pellegrini JD, De AK, et al. Both T-helper-1- and T-helper-2-type lymphokines are depressed in posttrauma anergy. J Trauma. 1998;44(6):1037.

[240] Yamada R, Tsuchida S, Hara Y, et al. Apoptotic lymphocytes induced by surgical trauma in dogs. J Anesth. 2002;16(2):131–137.

[241] Bandyopadhyay G, De A, Laudanski K, et al. Negative signaling contributes to T-cell anergy in trauma patients. Crit Care Med. 2007;35(3):794–801.

[242] Venet F, Chung CS, Huang X, et al. Lymphocytes in the development of lung inflammation: a role for regulatory CD4+ T cells in indirect pulmonary lung injury. J Immunol. 2009;183(5):3472–3480.

[243] Hotchkiss RS, Monneret G, Payen D. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis. 2013;13(3):260–268.

[244] Le Tuulo Y, Panguault C, Gacouin A, et al. Early circulating lymphocyte apoptosis in human septic shock is associated with poor outcome. Shock. 2002;18(6):487–494.

[245] Inoue S, Sato T, Suzuki-Utsunomiya K, et al. Sepsis-induced hypercytokinemia and lymphocyte apoptosis in aging-accelerated Klotho knockout mice. Shock. 2013;39(3):311–316.

[246] Hotchkiss RS, Tinsley KW, Swanson PE, et al. Depletion of dendritic cells, but not macrophages, in patients with sepsis. J Immunol. 2002;168(5):2493–2500.

[247] Inoue S, Unsinger J, Davis CG, et al. IL-15 prevents apoptosis, reverses innate and adaptive immune dysfunction, and improves survival in sepsis. J Immunol. 2010;184(3):1401–1409.

[248] Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol. 1991;9(1):271–296.

[249] Hotchkiss RS, Tinsley KW, Swanson PE, et al. Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans. J Immunol. 2001;166(11):6952–6963.

[250] Toti P, De Felice C, Occhini R, et al. Spleen depletion in neonatal sepsis and chorioamnionitis. Am J Clin Pathol. 2004;122(5):765–771.

[251] Cl D, De K, Kiepiela P, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature. 2006;443(7109):350–354.

[252] Sharpe AH, Wherry EJ, Ahmed R, et al. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol. 2007;8(3):239–245.

[253] Felmet KA, Hall MW, Clark RS, et al. Prolonged lymphopenia, lymphoid depletion, and hypoprolactinemia in children with nosocomial sepsis and multiple organ failure. J Immunol. 2005;174(6):3765–3772.
[254] Hiramatsu M, Hotchkiss RS, Karl IE, et al. Cecal ligation and puncture (CLP) induces apoptosis in thymus, spleen, lung, and gut by an endotoxin and TNF-independent pathway. Shock. 1997;7(4):247–253.

[255] Kushwah R, Wu J, Oliver JR, et al. Uptake of apoptotic DC converts immature DC into tolerogenic DC that induce differentiation of Foxp3+ Treg. Eur J Immunol. 2010;40(4):1022–1035.

[256] Monneret G, Debard AL, Venet F, et al. Marked elevation of human circulating CD4+CD25+ regulatory T cells in sepsis-induced immunoparalysis. Crit Care Med. 2003;31(7):2068–2071.

[257] Inoue S, Suzuki-Utsunomiya K, Okada Y, et al. Reduction of immunocompetent T cells followed by prolonged lymphopenia in severe sepsis in the elderly. Crit Care Med. 2013;41(3):810–819.

[258] Venet F, Chung CS, Kherouf H, et al. Increased circulating regulatory T cells (CD4+CD25 (+)CD127 (-)) contribute to lymphocyte anergy in septic shock patients. Intensive Care Med. 2009;35(4):678–686.

[259] Leng FY, Liu JH, Liu ZJ, et al. Increased proportion of CD4+CD25+(+FoxP3(+)) regulatory T cells during early-stage sepsis in ICU patients. J Microbiol Immunol Infect. 2013;46(5):338–344.

[260] Luan YY, Yin CF, Qin QH, et al. Effect of regulatory T cells on promoting apoptosis of T lymphocyte and its regulatory mechanism in sepsis. J Interferon Cytokine Res. 2015;35(12):969–980.

[261] Girardot T, Rimmelé T, Venet F, et al. Apoptosis-induced lymphopenia in sepsis and other severe injuries. Apoptosis. 2017;22(2):295–305.

[262] Voll RE, Herrmann M, Roth EA, et al. Immunosuppressive effects of apoptotic cells. Nature. 1997;390(6658):350–351.

[263] Gogos CA, Drosou E, Bassaris HP, et al. Pro- versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. J Infect Dis. 2000;181(1):176–180.

[264] Gao Y, Herndon JM, Zhang H, et al. Antiinflammatory effects of CD95 ligand (FasL)-induced apoptosis. J Exp Med. 1998;188(5):887–896.

[265] Trinchieri G. Interleukin-10 production by effector T cells: the cells show self control. J Exp Med. 2007;204(2):239–243.

[266] Hedrich CM, Bream JH. Cell type-specific regulation of IL-10 expression in inflammation and disease. Immunol Res. 2010;47(1–3):185–206.

[267] Groux H, Bigler M, De Vries JE, et al. Inhibitory and stimulatory effects of IL-10 on human CD8+ T cells. J Immunol. 1998;160(7):3188–3193.

[268] Li M, Guo W, Dong Y, et al. Elevated Exhaustion Levels of NK and CD8(+)+ T Cells as Indicators for Progression and Prognosis of COVID-19 Disease. Front Immunol. 2020;11:580237.

[269] He S, Zhou C, Lu D, et al. Relationship between chest CT manifestations and immune response in COVID-19 patients. Int J Infect Dis. 2020;98:125–129.

[270] Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620–2629.

[271] Wan S, Yi Q, Fan S, et al. Relationships among lymphocyte subsets, cytokines, and the pulmonary inflammation index in coronavirus (COVID-19) infected patients. Br J Haematol. 2020;189(3):428–437.

[272] Chen X, Huang J, Huang Y, et al. Characteristics of immune cells and cytokines in patients with coronavirus disease 2019 in Guangzhou, China. Hum Immunol. 2020;81(12):702–708.

[273] Rendeiro AF, Casano J, Vorkas CK, et al. Profiling of immune dysfunction in COVID-19 patients allows early prediction of disease progression. Life Sci Alliance. 2020;4(2):e202000955.

[274] Feng X, Li P, Ma L, et al. Clinical characteristics and short-term outcomes of severe patients with COVID-19 in Wuhan, China. Front Med. 2020;7:491.

[275] Zhao Y, Nie HX, Hu K, et al. Abnormal immunity of non-survivors with COVID-19: predictors for mortality. Infect Dis Poverty. 2020;9(1):108.

[276] Zhang B, Zhou X, Qiu Y, et al. Clinical characteristics of 82 cases of death from COVID-19. PLoS One. 2020;15(7):e0235458.

[277] Song J, Zeng M, Wang H, et al. Distinct effects of asthma and COPD comorbidity on disease expression and outcome in patients with COVID-19. Allergy. 2020;DOI:10.1111/all.14517.

[278] Bourkhissi L, Fakiri KE, Nassih H, et al. Laboratory abnormalities in children with novel coronavirus disease 2019. Clin Med Insights Pediatr. 2020;14:1179556520955177.

[279] Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatrica. 2020;109(6):1088–1095.

[280] Lu X, Zhang L, Du H, et al. SARS-CoV-2 Infection in Children. N Engl J Med. 2020;382(17):1663–1665.

[281] Su L, Ma X, Yu H, et al. The different clinical characteristics of coronavirus disease cases between children and their families in China - the character of children with COVID-19. Emerg Microbes Infect. 2020;9(1):707–713.

[282] Han H, Xu Z, Cheng X, et al. Descriptive, Retrospective Study of the Clinical Characteristics of Asymptomatic COVID-19 Patients. mSphere. 2020;5(5). DOI:10.1128/mSphere.00922-20.

[283] Diao B, Wang C, Tan Y, et al. Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19). Front Immunol. 2020;11:827.

[284] Notz Q, Schmalzing M, Wedekink F, et al. Pro- and Anti-Inflammatory Responses in Severe COVID-19-Induced Acute Respiratory Distress Syndrome-An Observational Pilot Study. Front Immunol. 2020;11:581338.

[285] Giovannetti A, Pierdominici M, Mazzetta F, et al. Unravelling the complexity of T cell abnormalities in common variable immunodeficiency. J Immunol. 2007;178(6):3932–3943.
[286] Chiappelli F, Khakshooy A, Greenberg G. CoViD-19 Immunopathology and Immunotherapy. Bioinformation. 2020;16(3):219–222.

[287] Sadeghi A, Tahmasebi S, Mahmood A, et al. Th17 and Treg cells function in SARS-CoV2 patients compared with healthy controls. J Cell Physiol. 2020; DOi:10.1002/jcp.30047.

[288] Brooks DG, Trifilo MJ, Edelmann KH, et al. Interleukin-10 determines viral clearance or persistence in vivo. Nat Med. 2006;12(11):1301–1309.

[289] Ejrnæs M, Cm F, Mm M, et al. Resolution of a chronic viral infection after interleukin-10 receptor blockade. J Exp Med. 2006;203(11):2461–2472.

[290] Wang F, Hou H, Luo Y, et al. The laboratory tests and host immunity of COVID-19 patients with different severity of illness. JCI Insight. 2020;5(10):10.

[291] Hou H, Zhang B, Huang H, et al. Using IL-2R/lymphocytes for predicting the clinical progression of patients with COVID-19. Clin Exp Immunol. 2020;201(1):76–84.

[292] Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420–422.

[293] Bucks CM, Norton JA, Boesteanu AC, et al. Chronic antigen stimulation alone is sufficient to drive CD8+ T cell exhaustion. J Immunol. 2009;182(11):6697–6708.

[294] Flament H, Rouland M, Beaudoin L, et al. Outcome of SARS-CoV-2 infection is linked to MAIT cell activation and cytotoxicity. Nat Immunol. 2021;22(3):322–335.

[295] Tan M, Liu Y, Zhou R, et al. Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou, China. Immunology. 2020;160(3):261–268.

[296] Mathew D, Giles JR, Baxter AE, et al. Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science. 2020;369(6508):6508.

[297] Hao S, Lian J, Lu Y, et al. Decreased B cells on admission associated with prolonged viral RNA shedding from the respiratory tract in coronavirus disease 2019: a case-control study. J Infect Dis. 2020;222(3):367–371.

[298] Qu J, Wu C, Li X, et al. Profile of Immunoglobulin G and IgM Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020;71(16):2255–2258.

[299] Wen W, Su W, Tang H, et al. Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing. Cell Discov. 2020;6(1):31.

[300] Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062.

[301] Zhao J, Yuan Q, Wang H, et al. Antibody responses to SARS-CoV-2 in Patients with novel coronavirus disease 2019. Clin Infect Dis. 2020;7(16):2027–2034.

[302] Zhang B, Zhou X, Zhu C, et al. Immune phenotyping based on the neutrophil-to-lymphocyte ratio and igg level predicts disease severity and outcome for patients with COVID-19. Front Mol Biosci. 2020;7:157.

[303] Molgora M, Bonavita E, Ponzetta A, et al. IL-1R8 is a checkpoint in NK cells regulating anti-tumour and anti-viral activity. Nature. 2017;551(7678):110–114.

[304] Giamarellos-Bourbonis EJ, Netea MG, Rovina N, et al. Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure. Cell Host Microbe. 2020;27(6):992–1000.e3.

[305] Jiang Y, Wei X, Guan J, et al. COVID-19 pneumonia: CD8(+) T and NK cells are decreased in number but compensatory increased in cytotoxic potential. Clin Immunol. 2020;218:108516.

[306] Delshad M, Tavakolnia N, Pourbagheri-Sigaroodi A, et al. The contributory role of lymphocyte subsets, pathophysiology of lymphopenia and its implication as prognostic and therapeutic opportunity in COVID-19. Int Immunopharmacol. 2021;95:107586.

[307] Qun S, Wang Y, Chen J, et al. Neutrophil-to-lymphocyte ratios are closely associated with the severity and course of non-mild COVID-19. Front Immunol. 2020;11:2160.

[308] Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020;71(15):762–768.

[309] Zhong Y, Cao Y, Zhong X, et al. Immunity and coagulation/fibrinolytic processes may reduce the risk of severe illness in pregnant women with COVID-19. Am J Obstet Gynecol. 2020;224(4):393.e1–393.e25.

[310] Liu J, Liu Y, Xiang P, et al. Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage. J Transl Med. 2020;18(1):206.

[311] Zuo Y, Yalavarthi S, Shi H, et al. Neutrophil extracellular traps in COVID-19. JCI Insight. 2020;5:11.

[312] Zou L, Dai L, Zhang Y, et al. Clinical characteristics and risk factors for disease severity and death in patients with coronavirus disease 2019 in Wuhan, China. Front Med (Lausanne). 2020;7:532.

[313] Moore KW, De Waal Malefyt R, Coffman RL, et al. 1 NTERLEUKIN –10 AND THE 1 NTERLEUKIN –10 R ECEPTOR. Annu Rev Immunol. 2001;19(1):683–765.

[314] D’Andrea A, Aste-Amezaga M, Valiante NM, et al. 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J Exp Med. 1993;178(3):1041–1048.

[315] Fiorentino DF, Zlotnik A, Mosmann TR, et al. IL-10 inhibits cytokine production by activated macrophages. J Immunol. 1991;147(11):3815–3822.

[316] Bogdan C, Vodovozt Y, Nathan C. Macrophage deactivation by interleukin 10. J Exp Med. 1991;174 (6):1549–1555.

[317] de Waal Malefyt R, Haanen J, Spits H, et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med. 1991;174(4):915–924.

[318] Tilg H, Van Montfrans C, Van den Ende A, et al. Treatment of Crohn’s disease with recombinant
human interleukin 10 induces the proinflammatory cytokine interferon gamma. Gut. 2002;50(2):191–195.

[319] Naing A, Papadopoulos KP, Autio KA, et al. Safety, antitumor activity, and immune activation of pegylated recombinant human interleukin-10 (AM0010) in patients with advanced solid tumors. J Clin Oncol. 2016;34(29):3562–3569.

[320] Chen J, Lau YF, Lamirande EW, et al. Cellular immune responses to severe acute respiratory syndrome coronavirus (SARS-CoV) infection in senescent BALB/c mice: CD4+ T cells are important in control of SARS-CoV infection. J Virol. 2010;84(3):1289–1301.

[321] Kim KD, Zhao J, Auh S, et al. Adaptive immune cells temper initial innate responses. Nat Med. 2007;13(10):1248–1252.